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CROSS-REFERENCE TO RELATED 
APPLICATIONS 
The present application is a 35 U.S.C. S371 national phase 
application from, and claiming priority to, International 
Application No. PCT/US2010/051176, filed Oct. 1, 2010, 
and published under PCT Article 21(2) in English, which 
claims priority to U.S. Provisional Application No. 61/248, 
202, filed Oct. 2, 2009, which applications are incorporated 
by reference herein in their entireties. 
BACKGROUND OF THE INVENTION 
Medical problems that affect bones, including fractures, 
degenerative diseases and inflammatory syndromes, impact 
millions of people worldwide. Bone fractures, lower back 
pain, osteoporosis, Scoliosis and other musculoskeletal prob 
lems generally require orthopedic intervention with the use of 
permanent or temporary medical Surgical fixation devices. 
The properties of these fixation devices play a key role in 
determining the Success and recovery time for the medical 
procedures. 
Surgical fixation devices, including plates, screws, pins, 
rods, anchors and Staples, are used in orthopedic Surgery 
procedures, such as: bone fracture fixation (Weiler et al., 
1988, Am. J. Sports Med. 26(1): 119-28); autograft ankle 
stabilization (Jeys et al., 2004, Am. J. Sports Med. 32(7): 
1651-59); reconstruction surgery of the anterior cruciate liga 
ment (ACL) and the posterior cruciate ligament (PCL) (Na 
kano et al., 2000, Clin. Biomech. 5(3):188-95); replacement 
of the intervertebral discs (Ella et al., 2005, J. Mat. Sci-Mat. 
Med. 16(7):655-62); and posterior spinal fixation (Evans et 
al., 2002, J. Mat. Sci-Mat. Med. 13(12): 1143-45). 
Metal Surgical fixation devices are often used to replace 
damaged or missing bone tissue due to their high initial fixa 
tion strength (Kurosaka et al., 1987, Am. J. Sports Med. 
15(3):225-29; Lambert, 1983, Clin. Orthop. Rel. Res. 172: 
85-89; Shelbourne & Nitz, 1990, Am. J. Sports Med. 18(3): 
292-99). However, metallic implant devices are not degrad 
able, leaving cavitations in the bone once the devices are 
removed. 
In recent years, Surgical fixation devices prepared with 
biocompatible polymers have been investigated as potential 
replacements of metallic fixation devices. Biocompatible 
polymers have the potential to revolutionize biomedical engi 
neering as scaffolds for hard and soft tissues, such as bone and 
blood vessels. Compared with conventional metal fixation 
devices, biocompatible polymer-based fixation devices have 
the advantages of causing no long-term implant palpability, 
no long-term temperature sensitivity, no stress shielding and 
no interference with post-operative diagnostic imaging. 
These advantages may lead to better bone healing, reduced 
patient trauma, reduced cost, elimination of need for a Sub 
sequent Surgery for implant removal, and fewer complica 
tions from infections. 
However, biocompatible polymer-based fixation devices 
still face challenges. The polymer or composite used in the 
devices should have good biocompatibility with the sur 
rounding tissue and have mechanical properties similar to the 
bone tissue being replaced. Furthermore, the polymer or com 
posite should be biodegradable so that it is gradually replaced 
by newly grown tissue (Claes et al., 1986, Akt. Traumatol. 
16:74-77; Rokkanen et al., 1985, Lancet 1 (8443): 1422-24). 













from a mechanical standpoint, especially when used as Sur 
gical fixation devices and bone scaffolds. Furthermore, cur 
rent biocompatible polymer-based Surgical fixation devices 
do not actively promote bone healing and regrowth, leaving 
voids in the tissue once the implanted device is fully 
degraded. There is thus a need to identify a polymer or com 
posite material that combines structural strength and bone 
tissue regrowth stimulation. 
Nanosized diamond powders (also known as nanodia 
monds or NDs) are produced by detonation synthesis in large 
volumes (Shenderova & McGuire, “Nanocrystalline Dia 
mond.” in “Nanomaterials handbook.Y. Gogotsi, Ed., 2006, 
CRC Taylor and Francis: Boca Raton, p. 203-37) and repre 
sent a new class of relatively inexpensive carbon nanomate 
rial with a broad range of potential applications, including 
composite materials. NDS have been used as components of 
sorbents, lubricating and polishing compositions and as addi 
tives to electrolytic and electroless deposition baths. 
NDs are composed of particles of about 5 nm in diameter 
and consist of an inert diamond core terminated with Surface 
chemical groups such as C—O, COOH, and OH (Lam et al., 
2008, ACS Nano 2(10):2095-2102), as shown in FIG. 1. 
When originally synthesized, the diamond core is often sur 
rounded by graphene shells and amorphous carbon (FIGS. 1a 
and 1b; Osswald et al., 2006, J. Am. Chem. Soc. 128(35): 
11635-42). 
NDs are a member of the nanocarbon family, but differ 
from other well-known nanomaterials, such as fullerenes and 
carbon nanotubes (Shenderova et al., 2002, Crit. Rev. Solid 
State Mat. Sci. 27(3–4):227-356). NDs exhibit the excellent 
mechanical, thermal and electrical properties of diamond at 
nanoscale, and actually outperform carbon nanotubes 
(CNTs) and other known materials. For example, the thermal 
conductivity of nanodiamonds (~2000 Wim' K') is of the 
same order as the highest reported for CNTs (6600 W.m. 
K') (Berber et al., Phys. Rev. Lett. 84(20):4613-16). How 
ever, in contrast to carbon nanotubes, ND is a good insulator. 
An attractive characteristic of NDs is their relative lack of 
toxicity and their biocompatibility. NDs have recently been 
reported to be the least toxic of all carbon nanomaterials 
(Puzyr et al., 2007, Diamond Relat. Mater. 16:2124-28; 
Huang et al., 2007, Nano. Lett. 7(11):3305-14; Mitura et al., 
2006, J. Achiev. Mat. Manuf. Eng. 16(1-2):9-16; Bakowicz 
Mitura, 2007, Surf. Coat, Technol. 201(13):6131-35; Lam et 
al., 2008, ACS Nano.2(10):2095-2102: Liu et al., 2007, Nano 
technol. 18(5):55102: Schrand et al., 2007, J. Phys. Chem. B 
111(1):2-7; Puzyr et al., 2007, Diamond Relat. Mater. 
16:2124-28). In contrast, the toxicity of CNTs is still debat 
able and raises concerns regarding their use in biological 
applications (Cherukuri et al., 2004, J. Am. Chem. Soc. 126 
(48): 15638-39; Cherukuri et al., 2006, Proc. Natl. Acad. Sci. 
U.S.A. 103: 18882-86). 
The small particle size and the low toxicity of NDs make 
them desirable for biological applications. Still, many poten 
tial applications of NDs, including in biomedical and com 
posite materials, remain unexplored. 
There remains a need in the art to identify novel materials 
that are compatible with biological systems and may have 
used in biomedical applications. Such as orthopedic Surgery. 
The present invention fulfills these needs. 
BRIEF SUMMARY OF THE INVENTION 
In one aspect, the invention includes a nanocomposite 
material comprising Surface-functionalized nanodiamonds 
and at least one biodegradable biocompatible polymer. 
US 9, 186,190 B2 
3 
In one embodiment, the at least one biodegradable biocom 
patible polymer is selected from the group consisting of 
polyglycolic acid, polylactic acid, poly-L-lactic acid, poly 
D/L-lactic acid with polyglycolic acid, poly-L-lactic acid-co 
glycolic acid, PDLLA with bioactive glass, PLGA with bio 
active glass, poly-L-lactic acid with B-tricalcium phosphate, 
poly-L-lactic acid with hydroxyapatite, polydioxanone, poly 
ethylene glycol, poly(s-caprolactone), polycaprolactone with 
alginate, polyhydroxybutyrate, polycarbonate, N-Vinyl pyr 
rolidone copolymers, polyorthoester, chitosan, poly(2-hy 
droxyethyl-methacrylate), hyaluronic acid and a hydrogel. In 
another embodiment, the at least one biodegradable biocom 
patible polymer is selected from the group consisting of 
polyglycolic acid, polylactic acid, poly-L-lactic acid, poly 
D/L-lactic acid with polyglycolic acid, poly-L-lactic acid-co 
glycolic acid, poly-L-lactic acid with B-tricalcium phosphate, 
and poly-L-lactic acid with hydroxyapatite. 
In one embodiment, the Surface-functionalized nanodia 
monds are prepared from chemically-active nanodiamonds. 
In another embodiment, the chemically-active nanodiamonds 
comprise chemical groups selected from the group consisting 
of carboxylate, carbonyl, amino and hydroxyl. In yet another 
embodiment, the Surface-functionalized nanodiamonds are 
prepared by peptide bond formation between an amine and a 
carboxylate group of the chemically-active nanodiamonds. In 
yet another embodiment, the amine is selected from the group 
consisting of octylamine, decylamine, undecylamine, dode 
cylamine, tridecylamine, tetradecylamine, pentadecylamine, 
hexadecylamine, heptadecylamine, dodecadecylamine, 
nonadecylamine and eicosylamine. In yet another embodi 
ment, the amine is octadecylamine. 
In one embodiment, the at least one biodegradable biocom 
patible polymer forms hydrogen-bond interactions with the 
Surface-functionalized nanodiamonds. In yet another 
embodiment, the at least one biodegradable biocompatible 
polymer forms a covalent bond with the surface-functional 
ized nanodiamonds. In yet another embodiment, the covalent 
bond is an amide bond formed between a carboxylate group 
of the at least one biodegradable biocompatible polymer and 
an amino group of the Surface-functionalized nanodiamonds. 
In yet another embodiment, the at least one biodegradable 
biocompatible polymer is selected from the group consisting 
of polyglycolic acid, polylactic acid, poly-L-lactic acid, poly 
D/L-lactic acid with polyglycolic acid, poly-L-lactic acid-co 
glycolic acid, poly-L-lactic acid with B-tricalcium phosphate, 
and poly-L-lactic acid with hydroxyapatite. 
In one embodiment, the material comprises 0.1% to 50% of 
the Surface-functionalized nanodiamonds. In another 
embodiment, the material further comprises a composition 
comprising at least one bioactive agent selected from the 
group consisting of a bone healing drug, growth factor, bone 
cell, bone stem cell, antibiotic, and anti-inflammatory drug. 
In another aspect, the invention comprises a Surgical fixa 
tion screw. The screw comprises an intercoruective porous 
shell, wherein the shell comprises a nanocomposite material 
comprising functionalized nanodiamonds and at least one 
biodegradable biocompatible polymer. The screw further 
comprises a hollow core within the shell, wherein the hollow 
core is closed on the posterior end of the screw and open on 
the anterior end of the screw. 
In one embodiment, the hollow core is optionally filled 
with a composition comprising at least one bioactive agent 
selected from the group consisting of a bone healing drug, 
growth factor, bone cell, bone stem cell, antibiotic, and anti 
inflammatory drug. In another embodiment, the posterior end 
is tapered with respect to the anterior end. In yet another 













embodiment, the anterior end is without head. In yet another 
embodiment, the posterior end is rounded and blunt. In yet 
another embodiment, the shell has controllable varying 
coarseness, whereby phase of the nanocomposite material 
around the hollow core is coarser than phase of the nanocom 
posite material on outside surface of the screw. In yet another 
embodiment, the controllable varying coarseness is achieved 
through injection molding. 
In yet another aspect, the invention includes a method of 
performing an orthopedic Surgery procedure in a patient. The 
method of the invention comprises the steps of: 
(a) inserting a Surgical fixation screw in at least one orifice 
of a bone or tissue of the patient. The screw comprises: 
(a.1) an interconnective porous shell, wherein the shell 
comprises a nanocomposite material comprising functional 
ized nanodiamonds and at least one biodegradable biocom 
patible polymer, and 
(a.2) a hollow core within the shell, wherein the hollow 
core is closed on the posterior end of the screw and open on 
the anterior end of the screw, and 
(b) filling the hollow core of the screw with a composition 
comprising at least one bioactive agent selected from the 
group consisting of a bone healing drug, growth factor, 
bone cell, bone stem cell, antibiotic, and anti-inflamma 
tory drug. 
In one embodiment, the at least one biodegradable biocom 
patible polymer is selected from the group consisting of 
polyglycolic acid, polylactic acid, poly-L-lactic acid, poly 
D/L-lactic acid with polyglycolic acid, poly-L-lactic acid-co 
glycolic acid, PDLLA with bioactive glass, PLGA with bio 
active glass, poly-L-lactic acid with B-tricalcium phosphate, 
poly-L-lactic acid with hydroxyapatite, polydioxanone, poly 
ethylene glycol, poly(e-caprolactone), polycaprolactone with 
alginate, polyhydroxybutyrate, polycarbonate, N-Vinyl pyr 
rolidone copolymers, polyorthoester, chitosan, poly(2-hy 
droxyethyl-methacrylate), hyaluronic acid and a hydrogel. In 
another embodiment, the posterior end is tapered with respect 
to the anterior end. In yet another embodiment, the screw has 
full-length taper. In yet another embodiment, the anterior end 
is without head. In yet another embodiment, the posterior end 
is rounded and blunt. In yet another embodiment, the shell has 
controllable varying coarseness, such that phase of the nano 
composite material around the hollow core is coarser than 
phase of the nanocomposite material on outside Surface of the 
screw. In yet another embodiment, the controllable varying 
coarseness is achieved through injection molding. 
BRIEF DESCRIPTION OF THE DRAWINGS 
For the purpose of illustrating the invention, there are 
depicted in the drawings certain embodiments of the inven 
tion. However, the invention is not limited to the precise 
arrangements and instrumentalities of the embodiments 
depicted in the drawings. 
FIG. 1, comprising FIGS. 1a-1d, is a series of high reso 
lution transmission electron microscope (HR-TEM) images 
(FIGS. 1a & 1c) and PM3 optimized molecular models 
(FIGS. 1b & 1d) illustrating the structure of as-produced 
(FIGS. 1a & 1b) and oxidized (FIGS. 1c & 1d) ND particles. 
FIG. 2, comprising FIGS. 2a-2d. is a schematic represen 
tation of the incorporation of 5-nm ND particles into poly 
mer-matrix composites. FIG. 2a depicts agglomerated par 
ticles, which lead to property degradation. FIG. 2b depicts 
inert filler, without chemical interactions with the polymer. 
FIG. 2C depicts polymer that is covalently bonded to disor 
dered carbon shells. FIG. 2d depicts polymer chains that are 
covalently bonded to the diamond surface. 
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FIG. 3, comprising FIGS. 3a-3b, is a schematic represen 
tation of covalently bound polymer-matrix composites using 
CNTs (FIG.3a) and NDs (FIG. 3b) as a filler. 
FIG. 4 is a schematic representation of the structure and 
selected physical properties of nanodiamond samples. The 
following legends apply: (a) as determined using transmis 
sion electron microscope (TEM); (b) as determined using soft 
X-ray absorption near-edge structure (XANES); (c) as 
reported by supplier NanoBlox, Inc. (Boca Raton, Fla., 
USA). The following codes apply: (1) carbon onion; (2) nano 
diamond; (3) fullerenic shell; (4) amorphous carbon; (5) 
graphite ribbon. 
FIG. 5 is a schematic representation of a bioactive interfer 
CCSCW. 
FIG. 6 is a schematic representation of a GCS (gradient 
cellular structure) mold with a heated core. The core tempera 
ture and the mold temperature may be controlled separately to 
create the desired thermal gradient. 
FIG. 7 is a graph depicting the FT-IR spectra of ND (linea), 
NDacyl chloride (lineb), ODA (octadecylamine; line c), and 
ND-ODA (lined). 
FIG. 8 is a graph depicting the UV Raman spectrum of 
ND-ODA powder. 
FIG. 9 is a graph demonstrating the particle size of ND 
ODA in toluene (line 1) and chloroform (line 2). The inset is 
a photograph of 0.01% wt suspensions of ND and ND-ODA 
in toluene. 
FIG. 10, comprising FIGS. 10a-10d, is a series of images 
comparing the nanodiamond dispersion in PLLA. The dis 
persion of ND-ODA in PLLA/chloroform solution was stable 
(day 1, FIG. 10a; and day 9, FIG. 10b). In contrast, most of 
NDs precipitated from PLLA/chloroform solution after one 
day (day 1, FIG. 10c; and day 2, FIG. 10d). 
FIG. 11 is a bar graph comparing the hardness of PLLA 
ND with different content of NDs and ND-ODA (% wt). 
FIG. 12, comprising FIGS. 12a-12b, is a series of graphs 
depicting the hardness and Young's modulus of PA-1 1/ND 
films with different contents of nanodiamond (FIG. 12a). 
Indentation curves for epoxy/ND composites with different 
contents of nanodiamond are depicted in FIG.12b. 
FIG. 13, comprising FIGS. 13a-13b, is a series of images 
depicting the bisbenzimide nuclear staining of adherent 
U2OS cells following 72 hours of seeding on pure PLLA 
(FIG. 13a, 100x) and ND-ODA/PLLA composite (0.5% wt 
ODA) (FIG. 13b, 100x) scaffolds. Images were captured by 
imaging the Surface of a strut on the outside of the scaffolds. 
FIG. 14 is a graph that demonstrates the heat flow during 
DSC measurement of pure PLLA, 3% wt ND-ODA/PLLA 
and 5% wt ND-ODA/PLLA composites. 
FIG. 15, comprising FIGS. 15a-15b, is a series of images of 
different porous structures obtained through different pro 
cessing conditions: FIG. 15a, without dwell time inside the 
intruder; and FIG. 15b, with dwell time inside the intruder. 
FIG. 16 is an image of a skin-core structure in injection 
molded blends. 
FIG. 17 is a bar graph demonstrating the molecular weight 
change of composites as a function of incubation time. 
FIG. 18, comprising FIG.18a-18d, illustrates the compos 
ites of the invention. FIG.18a is a schematic illustration of the 
manufacturing and use of ND-ODA/PLLA composites. FIG. 
18b is an illustrative molecular model of an ND-ODA par 
ticle. FIG. 18c is an illustrative comparison between 'C 
MASNMR spectra for UD90-ODA obtained via direct polar 
ization and H to C cross polarization. FIG. 18d is a repre 
sentation of a high resolution TEM illustrating an ND-ODA 
cluster where pristine nanodiamond particles are surrounded 













FIG. 19, comprising FIGS. 19a–19d, illustrates the charac 
terization of the ND-ODA particles. FIG. 19a is a graph 
illustrating the ND-ODA particle size in PLLA/chloroform 
solution. Particle size measurement showed 32 nm and 28 nm. 
ND-ODA agglomerates in 1% wt (curve 1) and 10% wt 
(curve 2) ND-ODA/PLLA-chloroform solution, respectively. 
The small particle size corresponded to ND-ODA aggregates 
composed of less than 5 ND-ODA particles in an aggregate 
cross-section. FIGS. 19b-d illustrate low resolution TEM 
micrographs of ND-ODA/PLLA thin cross-sections, sug 
gesting a uniform dispersion of small clusters of ND-ODA in 
the PLLA matrix at concentrations 1% (FIG. 19b), 3% (FIG. 
19C), and 10% (FIG. 19d). No micron-sized aggregates were 
observed. With the increasing ND-ODA concentration, inter 
connected chains were formed between ND-ODA clusters 
(FIG. 19d). 
FIG. 20, comprising FIGS. 20a-fillustrates representative 
load-displacement curves (FIG.20a) and stress-strain curves 
(FIG. 20b) of pure PLLA and ND-ODA/PLLA composites 
with 1% wt and 10% wt of ND-ODA. FIGS. 20a and 20b 
illustrate that the increase in ND-ODA content results in a 
pronounced reduction of creep and leads to an increase in 
hardness and Young's modulus of the nanocomposites. Com 
parison of Vickers indents on pure PLLA (FIG. 20c) and 10% 
ND-ODA/PLLA composite (FIG. 20d) provided a further 
evidence of a dramatic improvement in the elastic recovery of 
the ND-ODA/PLLA samples. FIG.20e illustrates XRD pat 
terns of pure PLLA and 10% wt ND-ODA/PLLA thin films. 
Upper curve in FIG.20e illustrates the XRD of a pure PLLA 
film. Bottom curve in FIG.20e illustrates the XRD of 10% wt 
of an ND-ODA/PLLA film. Both patterns showed Bragg 
peaks of PLLA, which are, in case of the pure PLLA film, 
seen atop of a strong amorphous halo indicating less crystal 
linity of PLLA as compared to the 10% wt ND-ODA/PLLA, 
Narrower and more intense peaks of 10% witND-ODA/PLLA 
also confirmed the higher crystallinity of the composite. FIG. 
20f is a table Summarizing the mechanical properties deter 
mined by depth sensing indentation. 
FIG. 21, comprising FIGS. 21a-d, illustrates SEM images 
of a 10% wt ND-ODA/PLLA thin film produced through 
solution casting. FIG. 21a illustrates the porous structure of 
the film, which facilitates cell attachment and growth. Due to 
the presence of ND-ODA in the PLLA matrix around pores, 
the film shows blue and red fluorescence (shown as light areas 
in the figures reproduced herein) under excitation with 360 
nm (FIG. 21b) and 555 nm (FIG. 21c). Fluorescence patterns 
coincided with the porous structure observed under SEM. 
The clear fluorescence of the 10% wt ND-ODA/PLLA Scaf 
fold (FIG. 21d) seen in the background of 7F2 osteoblasts 
after 3 days post-seeding indicated the possibility to monitor 
the composite degradation in situ through the fluorescence 
observation. 
FIG. 22, comprising FIGS. 22a-fillustrates the morphol 
ogy of 7F2 osteoblasts on pure PLLA and 10% wt ND-ODA/ 
PLLA. The morphology of these cells at 2 and 6 days of 
post-seeding on pure PLLA (FIGS. 22a and 22c) and 10% wt 
ND-ODA/PLLA (FIGS. 22b and 22d) are illustrated. Cell 
morphology of 2 days post-seeding on PLLA (FIG. 22a) and 
10% wt ND-ODA/PLLA (FIG.22b) suggests that the attach 
ment of osteoblasts on the surface of 10% wt ND-ODA/ 
PLLA scaffold was as good as on the surface of a pure PLLA 
scaffold. Staining for nuclei was bis-benzimide (blue) and for 
actin cytoskeleton-phalloidin (red). SEM images of 7F2 
grown on the different scaffolds after 6 days post-seeding: 
osteoblasts spread to confluence similarly on the Surface of 
pure PLLA (FIG. 22e) and 10% wt ND-ODA/PLLA (FIG. 
22?) scaffolds. 
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FIG. 23 is a bar graph illustrating real-time quantitative 
PCR analysis of gene expression for osteogenic marker genes 
alkaline phosphatase (ALP) and osteocalcin (OCN) in 7F2 
osteoblasts cultured for 48 h and 1 week on pure PLLA, 10% 
wt ND-ODA/PLLA and 10% wt UD90/PLLA post-seeding 
(*ANOVA: p-0.05). Data are expressed in meantstandard 
error (n=3). 
FIG. 24 is a bar graph illustrating a cytotoxicity test for ND 
and ND-ODA. Cell viability assay (alamarBlueTM (AB) 
based) of 7F2 mouse osteoblasts grown on tissue culture 
plastic (TCP) in the presence of ND or ND-ODA. Error bars 
represent the standard deviation for each sample (n-6). 
FIG. 25 is a bar graph illustrating biocompatibility test for 
ND-ODA/PLLA composites, Normalized increase in AB 
readings was monitored for 6 days in vitro 7F2 cell culture on 
pure PLLA, ND-ODA/PLLA (1-10% wt of ND-ODA), and 
control glass and TCP substrates. Metabolic activities were 
measured by AB assay every three days following the 24h 
seeding period. The data were normalized to the AB fluores 
cence reading at day 0. Error bars represent the standard 
deviation from the mean for each sample (n=6). 
DETAILED DESCRIPTION OF THE INVENTION 
The present invention relates to the discovery that a novel 
biomedical nanocomposite material comprising a biodegrad 
able biocompatible polymer and surface-functionalized 
nanodiamonds may be utilized for the development of scaf 
folds and surgical fixation devices for bone repair. These 
novel materials are strong from a mechanical standpoint and 
Suitable for use in Surgical fixation devices and bone scaf 
folds. These novel materials are biocompatible and biode 
gradable, and preferably stimulate the regeneration of the 
original biological material that is being replaced, avoiding 
cumbersome and potentially problematic follow-up proce 
dures. 
In one aspect, the invention provides a composition com 
prising a biodegradable biocompatible polymer and Surface 
functionalized nanodiamonds for implantation in a patient. 
The chemical moieties located on the surface of the nanodia 
monds interact with the polymer, ensuring that the nanodia 
mond particles are well dispersed within the polymer-nano 
diamond composite. Optionally, the composition further 
comprises at least one bioactive agent selected from the group 
consisting of a bone healing drug, growth factor, bone cell, 
bone stem cell, antibiotic, and anti-inflammatory drug. These 
bioactive agents may accelerate bone healing, bone growth, 
tissue growth and/or Surgical recovery. 
In another aspect, the invention provides a Surgical fixation 
device for use in a patient, wherein the device comprises a 
composition comprising a biodegradable biocompatible 
polymer and Surface-functionalized nanodiamonds. The 
device is comprised of materials that have a proven safety 
record and have sufficient mechanical strength. Optionally, 
the devise further comprises at least one bioactive agent 
selected from the group consisting of a bone healing drug, 
growth factor, bone cell, bone stem cell, antibiotic, and anti 
inflammatory drug. The device may further promote faster 
bone growth than existing devices. 
DEFINITIONS 
As used herein, each of the following terms has the mean 
ing associated with it in this section. 
Unless defined otherwise, all technical and scientific terms 
used herein generally have the same meaning as commonly 













invention belongs. Generally, the nomenclature used herein 
and the laboratory procedures in cell culture, molecular 
genetics, organic chemistry, and peptide chemistry are those 
well known and commonly employed in the art. 
As used herein, the articles “a” and “an refer to one or to 
more than one (i.e. to at least one) of the grammatical object 
of the article. By way of example, “an element’ means one 
element or more than one element. 
As used herein, the term “about will be understood by 
persons of ordinary skill in the art and will vary to some extent 
on the context in which it is used. 
As used herein, the term “biocompatible polymer refers to 
a polymeric material that does not cause inflammatory or 
immune response in the body. As used herein, the term “bio 
degradable polymer refers to a polymeric material that 
undergoes degradation when placed inside the body and gen 
erates non-toxic degradation products, which may be elimi 
nated by the body as such or metabolized into one or more 
non-toxic molecules. Non-limiting examples of biodegrad 
able biocompatible polymers are: polyglycolide or polygly 
colic acid (PGA); polylactide or polylactic acid (PLA); poly 
L-lactic acid (PLLA); poly-D/L-lactic acid with polyglycolic 
acid (PDLLA-co-PGA); poly-L-lactic acid-co-glycolic acid 
(PLGA); PDLLA with bioactive glass; PLGA with bioactive 
glass; poly-L-lactic acid with 3-tricalcium phosphate (PLLA 
TCP); poly-L-lactic acid with hydroxyapatite (PLLA-HA); 
polydioxanone (PDS); polyethylene glycol (PEG); poly(e- 
caprolactone) (PCL); polycaprolactone (PCL) with alginate: 
polyhydroxybutyrate (PHB); polycarbonate (PC); N-vinyl 
pyrrolidone copolymers; polyorthoester, chitosan, poly(2- 
hydroxyethyl-methacrylate) (PHEMA): hyaluronic acid and 
hydrogels. 
As used herein, the terms "nanodiamond”. “nanodiamond 
particle'. “ND” and “nanosized diamond powder are used 
interchangeably and refer a carbon nanomaterial composed 
of particles with about 5 nm in diameter consisting of an inert 
diamond core and Surface chemical groups. 
As used herein, the term “patient” refers to a human or a 
non-human animal. Non-human animals include, for 
example, livestock and pets, such as ovine, bovine, porcine, 
canine, feline and murine mammals, as well as reptiles, birds 
and fish. Preferably, the patient is human. 
Biodegradable Polymers for Use in Surgical Fixation Devices 
Increased interest in biodegradable Surgical tools for bone, 
ligament, tendon and graft fixations has led to the develop 
ment of Surgical fixation devices made of biopolymeric mate 
rial. Biodegradable polymers of synthetic and natural origin, 
Such as, but not limited to, polyglycolide or polyglycolic acid 
(PGA), polylactide or polylactic acid (PLA), poly-L-lactic 
acid (PLLA), poly-D/L-lactic acid with polyglycolic acid 
(PDLLA-co-PGA), poly-L-lactic acid-co-glycolic acid 
(PLGA), PDLLA with bioactive glass, PLGA with bioactive 
glass, poly-L-lactic acid with 3-tricalcium phosphate (PLLA 
TCP), poly-L-lactic acid with hydroxyapatite (PLLA-HA), 
polydioxanone (PDS), poly(e-caprolactone) (PCL), polyca 
prolactone (PCL) with alginate, polyhydroxybutyrate (PHB), 
polycarbonate (PC), N-vinyl pyrrolidone copolymers, poly 
orthoester, chitosan, poly(2-hydroxyethyl-methacrylate) 
(PHEMA). PEG (polyethylene glycol), hyaluronic acid and 
other hydrogels, were extensively studied. 
The concept of bioabsorbable (or biodegradable) material 
was introduced by Kulkarni and coworkers in the 1960s 
(Kulkarni et al., 1966, Arch. Surg. 93:839; Kulkarni et al., 
1971, J. Biomed. Mater. Res. 5: 169-181). In the last decades, 
these materials have been used in many orthopaedic applica 
tions such as bone Substitution, repair of bone fractures (in 
cluding ligament fixation), cartilage, meniscus and interver 
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tebral disc. They are used as Sutures, rods, screws, pins and 
plates (Ciccone et al., 2001, J. Am. Acad, Orthop. Surg. 
9:280-288). 
The bioabsorbable polymers included in the invention may 
be processed following similar procedures as those used for 
thermoplastics. They may be melted and extruded, molded by 
injection or compression or solvent cast, but the presence of 
moisture must be carefully controlled, because their hydro 
lytic sensitivity leads to a significant decrease in the materi 
als molecular weight. Therefore, the polymer included in the 
invention has to be kept completely dry before thermally 
processing, and its contact with moisture during the process 
ing must be avoided. 
Biodegradation of the biopolymers included in the inven 
tion is mainly caused by hydrolysis of the polymer chain 
backbone and to a lesser extent by enzymatic activity (Vert & 
Li, 1992, J. Mater. Sci. Mater. Med. 3:432-446; Li & McCar 
thy, 1999, Biomaterials 20:35-44). Degradation times depend 
on multiple factors, such as polymer crystallinity, molecular 
weight, thermal history, porosity, monomer concentration, 
geometry and the location of the implant. 
The biopolymers included in the invention comprise PLA, 
PDS, PGA, and PLGA, which are amongst the most com 
monly used synthetic, biodegradable polymers, with an 
extensive U.S. FDA approval history (Ella et al., 2005, J. Mat. 
Sci.-Mat. Med. 16(7):655-662; Huh et al., 2005, Drug Del. 
Tech. 3(5):52-58). 
PGA is a highly crystalline hydrophilic polymer, which 
tends to lose its mechanical strength rapidly (50% loss over a 
period of 2 weeks). Upon implantation, PGA degrades in 
about 4 weeks and can be completely absorbed in 4-6 months 
(Grayson et al., 2005, Biomaterials 26(14):2137-2145; Ouy 
anget al., 2002, Mat. Sci. & Eng. C: Biomim. Supramol. Syst, 
20(1-2): 63-69; Zhang et al., 2006, Pol. Degr. Stab. 91(9): 
1929-1936; Panyam et al., 2003, J. Contr, Rel. 92(1-2):173 
187; Oh et al., 2006, J. Mat. Sci-Mat. Medicine 17(2):131 
137; Valimaa & Laaksovirta, 2004, Biomaterials 25(7-8): 
1225-1232; Habraken et al., 2006, J. Biomat. Sci.-Pol. Ed. 
17(9): 1057-1074). 
PGA is more hydrophilic and PLA has a high modulus that 
makes it more Suitable for load-bearing applications. For 
PLGA copolymers, the mechanical strength and the degrada 
tion rate depend on the ratio of PLA/PGA. As the content of 
PLA in the PLGA copolymer increases, the copolymer 
becomes mechanically stronger and degrades more slowly. In 
the case of PLA, PLGA and PGA, the final products of the 
polymer degradation are the acidic monomers (lactic acid and 
glycolic acid, respectively) that are metabolized to ATP, water 
and CO (Brady et al., 1973, J. Biomed. Mater. Res. 7:155 
166). PLGA degradation is also influenced by other factors 
including the polymer chain length and characteristics of the 
Surrounding medium. 
Chitosan, PHEMA, PEG and hyaluronic acid are biopoly 
mers also included in the invention. They are among the most 
relevant hydrogels used in the generation of biomaterials. In 
hydrogels the bonding of hydrophilic macromolecules by 
means of covalent hydrogen and ionic bonds form a three 
dimensional network that is able to retain large amounts of 
water in their structure. These types of polymers are useful in 
cartilage, ligaments, tendons and intervertebral disc repair 
applications (Ambrosio et al., 1996, J. Mater. Sci, Mater. 
Med. 7:525-530). Chitosan is a weak cationic polysaccharide 
obtained by extensive deacetylation of chitin and composed 
essentially of B(1->4) linked glucosamine units together with 














Nanodiamonds as Fillers 
Nanodiamonds (NDs) are comprised of particles that are 
about 5 nm in diameter. In one embodiment, the NDs used in 
the invention vary in diameter from 0.1 nm to 50 nm. In 
another embodiment, the NDs used in the invention vary in 
diameter from 0.5 nm to 25 nm. In yet another embodiment, 
the NDs used in the invention vary in diameter from 1 nm to 
10 nm. In yet another embodiment, the NDs used in the 
invention vary in diameter from 2 nm to 8 nm. In another 
embodiment, the NDs used in the invention vary in diameter 
from 4 nm to 6 mm. 
The use of NDs as fillers within the invention is advanta 
geous because of the high matrix/filler interface area when the 
size of the filler particles approaches nanometer domain. By 
dispersing a mere 1% Vol of a nanoparticle of radius ~2 nm in 
a polymer (interfacial thickness ~6 nm), the Volume fraction 
occupied by the interface region is ~63%, Suggesting that 
more than half of the composite is affected by the presence of 
the second-phase particles (Winey & Vaia, 2007, MRS Bul 
letin 32:314-319). Thus, being well dispersed, the NDs 
included in the invention improve properties of the compos 
ites at very low concentrations without compromising the 
properties of the matrix. Furthermore, the ability of nanopar 
ticles, such as the NDs of the present invention, to penetrate 
through blood-brain barrier is unique and may be utilized in 
drug delivery systems (Kreuter, 2004, J. Nanosci. Nanotech 
nol. 4(5):484-488; Muller & Keck, 2004, J. Nanosci. Nano 
technol. 4(5):471-483). 
Surface-Functionalized Nanodiamonds and Chemically-Ac 
tive Nanodiamonds 
Non-functionalized ND particles tend to form unusually 
tight aggregates (Krueger, 2008, J. Mater. Chem., 18:1485 
1492). Mixing non-functionalized ND particles with a poly 
mer typically results in poor dispersion with micron-sized 
nanodiamond agglomerates embedded in the matrix (FIG. 
2a). Aggregated ND particles do not produce any property 
improvement for the composite, acting rather as defects and 
often leading to deterioration in mechanical properties. 
By contrast, functionalized NDS tend not to aggregate 
within the composite, but rather produce a uniform distribu 
tion of NDs in the composite (FIG. 2b). Even when well 
dispersed, however, the NDs act merely as conventional 
nanofillers with high hardness, performing similar to other 
ceramic nanoparticles (such as silica or clay) and leading to 
only moderate improvements in properties. In other words, 
good dispersion of the nanoparticles in the composite is not 
sufficient to ensure that the composite will have superior 
mechanical and thermal properties. A strong interface 
between the surface derivatized NDs and the matrix must also 
be present to ensure Superior mechanical properties for the 
corresponding composite, and methods must be developed 
for the rationale modification of the surface of the ND par 
ticle. 
In one embodiment, the strong interface between the Sur 
face derivatized NDs and the matrix is obtained by hydrogen 
bonds between the matrix and the surface derivatized NDs. In 
another embodiment, the strong interface between the surface 
derivatized NDs and the matrix is obtained by covalent bonds 
between the matrix and the surface derivatized NDs. These 
bonds are favored because surface derivatized NDs present a 
large number of functional groups on their Surface and are 
thus able to engage in multiple interactions (FIG. 3b). On the 
other hand, CNTs have only a small number of functional 
groups, located at the end of the tubes, and are thus limited in 
their ability to interact with the matrix (FIG.3a). 
Nanodiamonds included in the invention may be obtained 
from commercial sources, such as NanoBlox, Inc. (Boca 
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Raton, Fla., USA). This manufacturer provides nanodia 
monds in different grades: UD50, UD90 and UD98 grades, 
wherein the number in the grade roughly corresponds to the 
diamond-to-graphite ratio in the material. The properties of 
Such materials are Summarized in FIG. 4. 
Nanodiamonds included in the invention may present 
chemical groups on their Surface. Such nanodiamonds are 
generally referred to as “chemically-active nanodiamonds.” 
Chemically-active nanodiamonds may be manipulated by 
standard chemical methods to yield derivatized nanodia 
monds, such as Surface-functionalized nanodiamonds. 
In one embodiment, Surface-functionalized nanodiamonds 
are prepared by chemical modification of chemically-active 
nanodiamonds. In another embodiment, chemically-active 
nanodiamonds are themselves Surface-functionalized nano 
diamonds and are used as Such within the invention. 
Generation of chemically-active NDs included in the 
invention may be done in numerous ways, including tradi 
tional gas and wet chemistry (Osswald et al., 2006, J. Am. 
Chem. Soc. 128(35): 11635-11642; Mochalin et al., 2007, 
“High Temperature Functionalization and Surface Modifica 
tion of Nanodiamond Powders. In "Materials Research Soci 
ety Symposium Proceedings. Boston, Mass., USA, Vol. 
1039, No. 1039-P11-03). These methods allow for the gen 
eration of chemically-active nanodiamonds with different 
Surface functional groups, which may be used as handles to 
introduce chemical groups on the surface of the NDs (“sur 
face derivatization'). 
Among the methods for generating chemically-active NDS 
that are contemplated by the invention are air oxidation, 
hydrogenation, chlorination and ammonia treatment (Mocha 
lin et al., 2009, Mater. Res. Soc. Symp. Proc. 1039, 1039 
P11-03). 
In one embodiment of the invention, the chemically-reac 
tive NDs are prepared by air oxidation of NDs. Air oxidation 
(or oxidative purification) affords NDs free of amorphousand 
graphitic sp°-bonded carbon. 
Oxidative purification may be conducted under isothermal 
conditions using a THM600 Linkam heating stage (Linkam 
Scientific Instruments Ltd., Tadworth, Surrey, UK) and a tube 
furnace, and under non-isothermal conditions using a ther 
mobalance (Perkin-Elmer TGA 7. Shelton, Conn., USA). 
Isothermal experiments include two steps: (i) rapid heating at 
50° C./min to the selected temperature and (ii) isothermal 
oxidation for 5 hours in ambient air at atmospheric pressure. 
In one embodiment, the temperature range for oxidation of 
the ND samples investigated is 400-430° C. 
Under these conditions, the purity of ND may become 
comparable to that of microcrystalline diamond. Metal impu 
rities, which are initially protected by carbon shells in the 
commercial samples, generally become accessible after oxi 
dation and are completely removed by further treatment in 
diluted acids. In addition to purification, air oxidation dra 
matically changes the surface chemistry of ND (FIG. 1). 
Oxidation of the nanodiamond particles results in nanopar 
ticles covered by oxygen-containing functional groups such 
as C—O, COOH, and OH, with a decrease in the content of 
C-H groups. Carboxyl groups can be easily deprotonated in 
basic media, thus aqueous Suspensions of the oxidized ND 
have lower aggregation tendencies at pH>7. 
In another embodiment of the invention, the chemically 
reactive NDs are prepared by high temperature treatment of 
NDs in H atmosphere. In yet another embodiment, the high 
temperature treatment of NDs in H atmosphere is for 2 hours 
at 800° C. This treatment increases the content of C H 
containing groups and completely removes C=O groups as a 














tion (I). H annealing may not significantly remove non 
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In yet another embodiment of the invention, the chemi 
cally-reactive NDs are prepared by chlorine (Cl) treatment 
of NDs for 1 hour at 400° C. This treatment yields acyl 





O-R -e- C 
Vco = 1770 cm Vco = 1810 cm 
where R is H or a carbon-based group, such as CH. Chlori 
nation may also remove carbon from the material due to the 
formation of volatile CC1. 
In yet another embodiment of the invention, the chemi 
cally-reactive NDs are prepared by ammonia treatment of 
NDs for 1 hour at 850° C. This treatment may give rise to 
NH-containing groups on nanodiamonds. This treatment 
may also give rise to C. H. C=N and O H containing 
Surface functionalities. 
Functionalization of the Surface of ND Particles 
In one embodiment, the surface of the chemically-active 
nanodiamond particles included in the invention comprises 
carboxylic groups (—COOH). Chemically-active NDs with 
COOH Surface groups have good dispersion stability in aque 
ous solutions at basic pH (Osswald et al., 2006, J. Am. Chem. 
Soc. 128(35): 11635-11642). Carboxylic groups on the sur 
face of chemically-active nanodiamonds may be derivatized 
using methods known to those skilled in the arts. 
As a non-limiting example, the carboxylic groups on the 
Surface of chemically-active nanodiamonds may be reacted 
with an activating agent, Such as, but not limited to, EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide), DCC 
(dicyclohexylcarbodiimide) or DIC (N,N'-diisopropylcarbo 
diimide), in an inert Solvent such as, but not limited to, dichlo 
romethane, tetrahydrofuran or dimethylformamide, and then 
reacted with a primary or secondary amine, yielding Surface 
functionalized NDs with immobilized amides. 
In one embodiment, the amine is selected from the group 
consisting of octylamine, decylamine, undecylamine, dode 
cylamine, tridecylamine, tetradecylamine, pentadecylamine, 
hexadecylamine, heptadecylamine, dodecadecylamine, 
nonadecylamine and eicosylamine. In another embodiment, 
the amine is octadecylamine. 
In another non-limiting example, the carboxylic groups on 
the surface of chemically-active NDs may be reacted with a 
chlorinating agent. Such as, but not limited to, thionyl chlo 
ride, phosgene, diphosgene or triphosgene, in an inert Solvent 
such as, but not limited to, dichloromethane, tetrahydrofuran 
or dimethylformamide, and then reacted with a primary or 
secondary amine, yielding Surface-functionalized NDS with 
imnobilized amides. 
In another embodiment, the surface of the chemically 
active nanodiamond particles included in the invention com 
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prises amino groups (-NH2). Amino groups may be intro 
duced on the Surface of the chemically-active nanodiamonds 
by treating nanodiamonds with ammonia at high temperature. 
Amino groups may also be introduced on the Surface of the 
chemically-active nanodiamonds by attaching bisamines to 
nanodiamonds containing Surface carboxylic groups. 
As a non-limiting example, the carboxylic groups on the 
Surface of chemically-active nanodiamonds may be reacted 
with (i) an activating agent, Such as, but not limited to, EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide), DCC 
(dicyclohexylcarbodiimide), or DIC (N,N'-diisopropylcarbo 
diimide), in an inert Solvent such as, but not limited to, dichlo 
romethane, tetrahydrofuran or dimethylformamide, or (ii) 
with a chlorinating agent, such as, but not limited to, thionyl 
chloride, phosgene, diphosgene or triphosgene, in an inert 
solvent such as, but not limited to, dichloromethane or tet 
rahydrofuran. The material may then be reacted with a 
bisamine, in an inert solvent such as, but not limited to, 
dichloromethane, tetrahydrofuran or dimethylformamide. In 
one aspect, the bisamine may have both amine groups in 
unprotected form, in which case the reaction yields an immo 
bilized amide with a free amino group. In another aspect, the 
bisamine may have one unprotected amino group and one 
protected amino group, wherein the protective group may be, 
for example, t-butoxycarbonyl (Boc) or fluorenylmethoxy 
carbonyl (Fmoc). In this case the reaction yields an immobi 
lized amide with a protected amino group. The protective 
group may be removed using conditions well known in the 
art, such as treatment with trifluoroacetic acidorhydrochloric 
acid in the case of the Boc protective group, or treatment with 
piperidine in dimethylformamide in the case of the Fmoc 
protective group. This procedure yields surface-functional 
ized NDS with amides containing free amines. 
Formation of Bonds Between Surface-Functionalized ND 
Particles and Matrix 
An important aspect of be considered in the preparation of 
nanodiamond-polymer composites included in the invention 
is the purity level of the starting ND particles. The content of 
non-diamond phase in as-produced or commercially avail 
able NDs may be as high as 75% wt. Purification of as 
received or crude NDS using modification methods such as, 
but not limited to, air oxidation, hydrogenation, chlorination 
and ammonia treatment, and optional mechanical methods 
Such as, but not limited to, treatment with acidic Solutions, 
results in non-diamond carbon removal and generation of a 
material with the surface uniformly terminated by specific 
functional groups. In a non-limiting example, selective air 
oxidation of as-received ND in controlled conditions may 
increase the content of diamond phase from ~25 up to ~95% 
wit, and convert diverse surface functional groups of non 
purified ND into C=O and COOH (Osswald et al., 2006, J. 
Am. Chem. Soc. 128(35): 11635-11642). 
In one embodiment, the nanocomposite material com 
prises 0.1% to 50% of surface-functionalized NDs. In another 
embodiment, the nanocomposite material comprises 0.5% to 
50% of surface-functionalized NDs. In yet another embodi 
ment, the nanocomposite material comprises 0.75% to 40% 
of surface-functionalized NDs. In yet another embodiment, 
the nanocomposite material comprises 1% to 30% of surface 
functionalized NDs. In yet another embodiment, the nano 
composite material comprises 2% to 25% of surface-func 
tionalized NDs. In yet another embodiment, the 
nanocomposite material comprises 3% to 20% of surface 
functionalized NDs. In yet another embodiment, the nano 
composite material comprises 4% to 20% of surface-func 
tionalized NDs. In yet another embodiment, the 













functionalized NDs. In yet another embodiment, the nano 
composite material comprises 6% to 12% of surface-func 
tionalized NDs. In yet another embodiment, the 
nanocomposite material comprises 8% to 12% of surface 
functionalized NDs. 
A strong interface between the surface-functionalized NDs 
included in the invention and the matrix must be present to 
ensure improved mechanical properties for the composite 
contemplated in the invention. One Such strong interface may 
be obtained by forming strong covalent or non-covalent 
bonds between the surface-functionalized NDs and the 
matrix. In this case, for each polymer matrix, the Surface 
functionalized NDs would contain surface groups capable of 
forming strong hydrogen bonds or covalent bonds with the 
molecules of polymer matrix (FIG. 2d). Covalent bond for 
mation between the purified surface-functionalized ND par 
ticles and polymer matrix will eventually lead to a “super 
composite', a material that should fully realize the superior 
mechanical and thermal properties of ND nanodiamond. 
In a non-limiting example, PLLA matrix and NH2-termi 
nated ND may be used to generate a covalently bound ND 
matrix composite. PLLA matrix contains free terminal 
—COOH groups, which may be reacted with NH-termi 
nated ND in the presence of a coupling reagent, such as, but 
not limited to, DCC (dicyclohexylearbodiimide), EDC 
(1-ethyl-3-(3-dimethylaminopropyl)carbodiimide), or DIC 
(N,N'-diisopropyl-carbodiimide), in an inert solvent such as, 
but not limited to, dichloromethane, tetrahydrofuran or dim 
ethylformamide. This reaction results in amide bonds 
between the surface-functionalized ND particle and PLLA 
chains, as shown in reaction (III), 
O CH3 
H3C O OH + Niro 




HC O S-GE) + H2O O pi 
O CH O 
In another non-limiting example, PLLA matrix and—NH 
or —COOH groups on the surface of functionalized ND 
powders may be used to form strong hydrogen bonds between 
the PLLA matrix and the ND particles. 
In yet another non-limiting example, PLLA matrix and 
HO-terminated ND may be used to generate a covalently 
bound ND-matrix composite. PLLA matrix contains free ter 
minal —COOH groups, which may be esterified with OH 
terminated ND in the presence of a coupling agent such as 
DCC. Alternatively, the PLLA matrix may be treated with a 
chlorinating agent, such as thionyl chloride, to effect conver 
sion of the carboxylic acid groups into acyl chloride groups. 
This material may then be reacted with HO-terminated ND to 
yield ester-linked ND-PLLA composites. Such chemical 
approaches may be extended to other polymers contemplated 
in the invention, depending on the specific functional groups 
that they contain. 
(III) 
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Surgical Fixation Devices Containing Derivatized ND Par 
ticles 
Surgical fixation devices are crucial for the treatment of 
bone-related problems. For example, more than 90,000 ante 
rior cruciate ligament (ACL) reconstructive Surgeries are per 
formed annually worldwide (Bangash, "Trauma An Engi 
neering Analysis. Springer Berlin Heidelberg, 2007). This 
procedure involves replacing the torn ligament with new tis 
Sue (a graft), repairing and/or replacing the damaged ACL and 
dealing with knee instability, pain and recurrent Swelling. For 
this, Small holes are drilled in the bone, and the graft is passed 
through these holes. These grafts are then held in place and 
fixed using a wide range of Surgical devices, such as plates, 
Staples, anchors, interference screws and transverse pins. 
Good initial fixation of the properly positioned and tensioned 
graft is critical. 
ACL procedures and other in bone/tissue structure fixation 
procedures would benefit from the development of a novel 
Surgical fixation device that combines the property of Sup 
porting weight and providing Support with the ability to even 
tually allow for regrowth of the bone material. The devices 
contemplated in the present invention address these uses. 
The bioactive surgical fixation devices of the present inven 
tion are multi-functional. On one hand, they have the neces 
sary stiffness and strength to be used in Surgical procedures. 
On the other hand, they comprise a permeable medium that is 
able to deliver bioactive agents to the environment. 
Nature is an excellent producer of similar multifunctional 
structures, e.g., wood, eggshell, wheat and rice, bone, skin, 
and others. These naturally porous materials all have a gra 
dient cellular structure (GCS), with the porosity distributed in 
space so as to maximize the overall performance of the struc 
ture (Zhang et al., 2005, J. Zhejiang Univ. Sci. 6a(10):1095 
1099: Kumar, 1993, Cell. Pol. 12(3):207-223; Suh, 2003, 
Macromol. Symp. 201:187-201: Gong et al., 2005, Int. Pol. 
Proc. 2002):202-214; Kitimasak et al., 2003, Science Asia 
29:95-98). 
In bone, regions of dense “cortical’ bone abut on regions of 
low-density “trabecular bone. With pore sizes decreasing 
from the core to the exterior, bone is able to maintain a highly 
permeable core and yet provide outer wall structural integrity. 
In the avian eggshell, a GCS achieves desired mechanical 
performance and a necessary permeability. From inside to 
outside, the pore size varies from several 100 nm to a couple 
of microns (Zhanget al., 2005; Kitimasak et al., 2003), allow 
ing for exchange of matter between the outside and inside of 
the eggshell while ensuring enough strength to prevent the 
shell from cracking caused by collision or impact. In Sum 
mary, GCSs have the ability to integrate different, often con 
tradictory, functions and achieve an optimized design. 
The biomimetic devices of the invention present high struc 
tural integrity, with regulated variation of permeability 
throughout the device. Furthermore, variation of mechanical 
properties of the structure of the device of the invention may 
be controlled to match other materials at the interface of the 
device and the body. 
Composite Surgical Fixation Devices 
Surgical fixation devices have to be biocompatible, i.e., 
they may not cause an inflammatory or immune response in 
the body. However the current devices lack bioactive features. 
Specifically, these devices do not actively promote bone heal 
ing and regrowth, Subsequently leaving Voids in the tissue 
once the implanted Surgical fixation device is removed (metal 
device) or fully degraded (biopolymer device). 
The composite bioactive fixation device of the invention 
promotes bone healing and regrowth, based on the following 













strong enough to withstand the mechanical stress during 
insertion and post-operative activity. Its degradation may be 
controllable to coincide with the rate of tissue growth. The 
fixation device of the invention may avoid the need for future 
implant removal operation due to adverse reactions or 
implant loosening. 
The Surgical fixation devices of the invention, Such as, but 
not limited to, Surgical screws, have two unique and critical 
components: (1) inclusion of nanodiamonds, which dramati 
cally improve the mechanical properties of the biomaterials 
and serve as a biocompatible non-toxic scaffold to Support 
growing cells; (2) porous shell structures for gradual release 
of hydrogels containing bone healing drugs (such as bispho 
sphonates, alendronate, ibandronate, risedronate, Zoledronic 
acid, estrogen, raloxifene, calcitonin, or teriparatide), growth 
factors (such as bone morphogenetic protein 2 (BMP2), lacto 
ferrin, OxiplexTM (FzioMed, San Luis Obispo, Calif.) or bone 
growth factor rhGDF-5), antibiotics (such as Vancomycin, 
clindamycin, tobramycin gentamycin, teicoplanin or syner 
cid, or combinations thereof), anti-inflammatory drugs, bone 
cells, and bone stem cells, from a center core. The composite 
bioactive Surgical devices of the invention also serve as scaf 
folds for osteoblasts to migrate into the screw, where they can 
proliferate/differentiate and finally form new bone tissue as 
the device degrades. 
In one embodiment, the orthopedic Surgical device is a 
sterile, single-use biodegradable and bioactive fixation sys 
tem comprising a composite comprising NDS and poly-L- 
lactic-co-glycolic acid (PLGA) or PLLA. 
In another embodiment, the device has embedded bioac 
tive reagents such as bone healing drugs, growth factors, bone 
cells, bone stem cells, antibiotics, and/or anti-inflammatory 
drugs, to accelerate bone?tissue healing and recovery. Until 
now there has been no reported work on bioactive Surgical 
fixation devices with gradient cellular wall/shell structure and 
nanodiamond reinforced polymers for bone tissue engineer 
ing. The device of the present invention is entirely composed 
of materials with a proven safety record and sufficient 
mechanical strength, and promotes faster bone growth than 
existing passive/inactive devices. 
To fulfill the above design criteria, the surgical fixation 
device of the invention has two unique and critical compo 
nents: (1) a core that is first used as the device driver interface 
and then, after the device insertion, is used as a reservoir to 
store Syringe-injected hydrogel containing bioactive materi 
als, and (2) an interconnective porous wall/shell, which 
allows local, controlled delivery of the biomaterials in ques 
tion. The porous device also serves as a scaffold for osteo 
blasts to migrate into it, where they can proliferate/differen 
tiate and finally form new bone tissue as the device degrades. 
In one embodiment of the invention, the Surgical fixation 
device is a screw, pin, rod, anchor or staple. 
In another embodiment of the invention, the Surgical fixa 
tion device is a screw. 
In yet another embodiment of the invention, a design for a 
bioactive interference screw is represented in FIG. 5. This 
screw may be used for ACL fixations, in a non-limiting 
example. 
The screw possesses a rounded blunt posterior portion to 
prevent graft damage. The screw is tapered and without head 
so that it will not protrude out of the drilled hole. The tapered 
feature is specifically designed to provide maximum pull-out 
strength in ACL reconstruction. The Screw is slightly more 
tapered at the tip to facilitate insertion taking into account the 
tight fit at this locale. In addition, these screws include full 
length tapers so that the highest insertion torque is only real 
ized once the screw is fully inserted, as to increase fixation 
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and pullout strengths (Agrawal & Athanasiou. “A New Tech 
nique to Control the pH in the Vicinity of Biodegradable 
Implants.” in Fifth World Biomaterials Congress, 1996, Tor 
onto, Canada; De Groot, “Degradable ceramics, in “Bio 
compatibility of Clinical Implant Materials. D. F. Williams, 
Ed., CRC Press: Boca Raton, Fla., 1981, pages 199-222). A 
reduced thread pitch (the axial distance per screw turn) eases 
insertion by effectively reducing the screw “lead’, which the 
screw uses to travel into the bone tunnel. This difference in 
“lead’ reduces the stress within the screw as it is turned, 
ensuring that the screw is not subjected to forces beyond the 
material limits. 
The design incorporates a tapered screw and a tapered 
driver, thus decreasing the insertion stress while maintaining 
fixation strength. This design minimizes driver stripping and 
screw breaking by optimizing stress distribution and force 
transfer. As a result, the tapered design reduces insertion 
torque, making insertion easier (Albee, Ann. Surg. 1920, 
71 (1):32-39; LeGeros et al., “Significance of the porosity and 
physical properties of calcium phosphate ceramics—Biodeg 
radation bioresorption. A Task Group Report'). 
After the screws are inserted in the bone or tissue, the 
hollow core of the screws may additionally be filled with 
bioactive materials like growth factors, drugs and/or cells at 
the time of Surgery in the operating room setting to stimulate 
bone growth. For maximum effectiveness, the bone adjacent 
to the screw and the bio-reagents in the core are connected 
with gradient cellular pores, creating a continuous system that 
accelerates bone regrowth upon insertion and filling the Void 
upon degradation of the screw (FIG. 5). 
Injection Molding of Controllable Porous Structures 
Functional porous materials with controllable porous 
structures, to be used within the invention, may be prepared 
by injection molding an immiscible polymer blend, with spa 
tially controlled thermal conditioning to adjust the phase size 
and its distribution. Controllable pore sizes and gradient 
porous structures may be obtained through control of the 
thermo-mechanical history of the blend during processing. 
This approach may be further developed for the production of 
a gradient porous biomaterial reinforced by nanodiamond 
and suitable for applications in implanted devices. 
In one embodiment of the invention, polymers such as, but 
not limited to, PLA, PGA, or PLGA, are first melt-blended 
with a sacrificial, immiscible polymer (e.g., polystyrene) in a 
batch mixer to ensure the development of a fine blend struc 
ture with phase size of micrometers. The blend is then injec 
tion molded into the mold cavity for the bioactive device 
(which may be a screw, in a non-limiting example). While 
inside the mold, the blend is thermally conditioned with 
higher temperature at the core and lower temperature at the 
Surface, resulting in the development of coarse phases at the 
core but fine phases at the surface. The interfacial surface 
tension between the two polymers causes coarsening of the 
phase structure at high-temperature regions. The gradient in 
phase size may be regulated by adjusting the thermal history. 
When the desired growth is reached, the mold is cooled and 
the screw is ejected. Finally, the sacrificial polymer in the 
screw is selectively dissolved to obtain desired porous struc 
tures. 
To make a porous screw with a gradient, special handling is 
needed to create a suitable thermal boundary condition (FIG. 
6). For this purpose, a thin cartridgeheater is embedded in the 
hexagonal core to control the core temperature. A separate 
heating/cooling unit is employed in the mold base. This setup 
allows differential control of temperature from the surface to 
the core of the molding polymer. The different thermal history 













ture, Particularly, it results in a coarser structure near the core 
and a finer one at the surface. A dwell time of a couple of 
minutes at an elevated temperature may result in a significant 
amount of structural coarsening. The desired structure may be 
approached through adjustment of the two temperatures, i.e., 
core and base temperatures. 
Established rapid mold heating techniques (Yao & Kim, 
2002, Pol. Eng. & Sci. 42(12):2471-2481;Yao & Kim, 2002, 
Pol-Plast. Eng. Technol. 41(5):819-832;Yao et al., 2006, Pol. 
Eng. Sci. 46(7):938-945) may be used to rapidly heat the core 
and the mold, thus facilitating in situ control to yield the 
desired thermal history. In one embodiment, a normal filling 
process with a filling time on the order of 1 second is used, 
followed by a prolonged holding stage of several minutes, to 
thermally condition the phase structure. The actual mold and 
core temperatures and the hold time depend on the desired 
phase structure that needs to be grown. An inverse design 
(Kang et al., 1998, J. Therm. Stresses 21(2):141-155) 
approach may be employed for optimizing the thermal his 
tory and achieving the desired phase structure. 
During selective dissolution, water and biocompatible sol 
vents are used as a first choice. If other solvents are needed, 
the extraction is followed by careful flushing in water to 
remove all solvent residues. Particularly, a PLA/PCL system 
may be tested for its suitability. PCL is another biocompatible 
and biodegradable polymer, and it may be extracted with 
acetic acid. However, the two polymers have very different 
melting temperature, thus increasing the processing diffi 
culty. 
Other more polar polymers such as polystyrene (PS) may 
also be tested. In the case of PS, extraction starts with cyclo 
hexanone, followed by an alcohol based solvent, and finally 
water. Alternatively, PLA (or PLGA) and PGA may be used to 
form a co-continuous phase morphology and Subsequently 
the PGA phase may be degraded to form a porous PLA 
structure. This approach is based on the fact that PGA has a 
much higher degradation rate than PLA. Such a system is 
fully biocompatible since no solvent is involved. Another 
advantage of this method is that degradation of the PGA 
phase can be induced in vivo, allowing the use of a fully dense 
screw during insertion. 
Mechanical and Biological Testing 
The most frequent complication associated with biode 
gradable screws is screw breakage during insertion (Evans et 
al., 2002, J. Mat. Sci.-Mat. Med. 13(12): 1143-1145; Barberet 
al., 2000, Biomaterials 21(24):2623-2629; Lee et al., 2005, 
Biomaterials 26(16):3249-3257). Material studies on the 
polymer-ND composite of the invention, including compres 
sion strength, tensile strength, Young's modulus, and pull-out 
strength, may shed light on the breakage problem. Compres 
sive and tensile tests may be performed using a Tenius Olsen 
H25KT single column materials testing machine (Tenius 
Olsen, Horsham, Pa., USA). The maximum torque that may 
be applied to the screw may be determined with a torque 
meter. Pullout/pushout experiments may be performed using 
wood, and model bone, such as polyurethane foams and Saw 
bones, both of which are established tests that approximate 
the mechanical properties of real bone. 
The resorption of the device of the invention in the body 
depends on the shape, size and site of implantation. The 
polymer resorbable composite should degrade in vivo in a 
manner consistent with healthy bone regeneration in bone 
augmentation and repair procedures. Without wishing to be 
bound by any theory, the fine particles of NDs are actively 
released together with fine particles of reduced-molecular 
weight PLGA, causing the structure to gradually degrade and 
shrink. This system leads to total repair of the bone once the 
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device is completely disintegrated. This in vivo situation may 
be simulated in vitro by incubating and maintaining the bio 
active screws under aseptic conditions in complete cell cul 
ture medium supplemented with 20% bovine serum. The 
decrease in molecular weight of the PLGA over time indi 
cates the progression of degradation. The weight loss is mea 
Sured over time and a comparison of cross-sectional images 
of the degrading bioactive device is made to determine the 
degradation rate of the device in vitro testing. 
ND Composite Material Biotesting on Toxicity and Biocom 
patibility 
Toxicity Screening 
Toxicity of the materials included in the invention may be 
tested using extraction assays. Extracts are prepared by incu 
bating Surgical device material for up to 30 days in protein 
containing culture medium. Human osteoblasts (ATCC, 
CRL-1 1372) are cultured in MEM culture medium supple 
mented with 10% fetal calf serum and antibiotics, with cell 
free medium as negative controls. Potential toxicity-induced 
changes in cell morphology and detachment are monitored by 
fluorescent and Scanning electron microscopy. Cell viability 
and proliferation are quantified over a 30-day period by using 
the Alamar blue assay (Mondrinos et al., 2006, Biomaterials 
27(25):4399-4408; Nikolaychiket al., 1996, J. Biomater. Sci. 
Polym. Ed. 7:881-891). 
Cell Attachment and Proliferation 
Cell attachment and proliferation may be assessed by seed 
ing composite disks with human osteoblasts. Composite 
materials are cast under aseptic conditions into 10-mm diam 
eter 1.5-mm thick disks, to fit in 24-well plates. Following 
seeding, cell viability is assayed for up to 30 days using the 
Alamar Blue assay (Nikolaychik et al., 1996), Cell distribu 
tion in the disks is quantified after fixation and sectioning (10 
um) by light microscopy, following staining with hematoxy 
lin and eosin, as well as by fluorescence microscopy of thicker 
sections (60 um) after staining the nuclei and microfilaments 
with, respectively, Hoechst 33258 and rhodamine phalloidin 
(Li et al., 2006, Biomaterials 27(13):2705-2715; Li et al., 
2005, Biomaterials 26(30):5999-6008). 
Those skilled in the art will recognize, or be able to ascer 
tain using no more than routine experimentation, numerous 
equivalents to the specific procedures, embodiments, claims, 
and examples described herein. Such equivalents were con 
sidered to be within the scope of this invention and covered by 
the claims appended hereto. For example, it should be under 
stood, that modifications in reaction conditions, including but 
not limited to reaction times, reaction size/volume, and 
experimental reagents, such as solvents, catalysts, pressures, 
atmospheric conditions, e.g., nitrogen atmosphere, and 
reducing/oxidizing agents, with art-recognized alternatives 
and using no more than routine experimentation, are within 
the scope of the present application. 
It is to be understood that wherever values and ranges are 
provided herein, all values and ranges encompassed by these 
values and ranges, are meant to be encompassed within the 
Scope of the present invention and should not be construed as 
an inflexible limitation on the scope of the invention. More 
over, all values that fall within these ranges, as well as the 
upper or lower limits of a range of values, are also contem 
plated by the present application. Moreover, all values that 
fall within these ranges, as well as the upper or lower limits of 
a range of values, are also contemplated by the present appli 
cation. The description of a range should be considered to 
have specifically disclosed all the possible Sub-ranges as well 
as individual numerical values within that range and, when 
appropriate, partial integers of the numerical values within 













6 should be considered to have specifically disclosed sub 
ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 
4, from 2 to 6, from 3 to 6 etc., as well as individual numbers 
within that range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. 
This applies regardless of the breadth of the range. 
The following examples further illustrate aspects of the 
present invention. However, they are in no way a limitation of 
the teachings or disclosure of the present invention as set forth 
herein. 
EXAMPLES 
The invention is now described with reference to the fol 
lowing Examples. These Examples are provided for the pur 
pose of illustration only, and the invention is not limited to 
these Examples, but rather encompasses all variations that are 
evident as a result of the teachings provided herein. 
Materials: 
Unless otherwise noted, all starting materials and resins 
were obtained from commercial Suppliers and used without 
purification. 
Nanodiamonds (NDs) of UD50, UD90 and UD98 grades 
were obtained from NanoBlox, Inc. (Boca Raton, Fla., USA). 
The number in the grade roughly corresponds to the diamond 
to-graphite ratio in the material, as shown in FIG. 4. 
Commercial and gas treated samples of NDs were charac 
terized by Raman spectroscopy, using a Renishaw RM2000 
UV Raman microspectrometer (0.325 nm) (Renishaw, 
Gloucestershire, UK); FTIR spectroscopy, using a Digilab 
Excalibur spectrometer (Digilab, Holliston, Mass.) with 
UMA 600 microscope; and High Resolution Transmission 
Electron Microscopy (HR-TEM) using a JEOL 2010F micro 
scope (JEOL, Tokyo, JP). 
Octadecylamine functionalized nanodiamond (ODA) 
powders were obtained from NanoBlox, Inc. (Boca Raton, 
Fla., USA). 
PLLA was purchased from PURAC (Gorinchem, Nether 
lands). 
All cell culture media and supplements were from Hyclone 
(Waltham, Mass.). Disposable tissue culture supplies were 
from Fisher Scientific (Pittsburgh, Pa.). 
Gas Treatment: 
Gas treatment has been performed in the apparatus 
described in the literature (Dash et al., 2004, Micropor. Meso 
por. Mat. 72C1-3):203-208) using air, argon, H., Cl, and 
NH. Air was of “breathing quality” and other gases were of 
“high purity” or “ultra high purity' grades as supplied by Air 
Gas (USA). 
The samples were treated according to the following pro 
tocol. ND powder (0.3-0.5 g) was placed into a quartz, boat, 
weighed and inserted into a quartz tube positioned inside a 
tube furnace. The furnace tube was isolated from the atmo 
sphere and purged with argon (30 ml/min) at room tempera 
ture for 1 hour to remove the ambient atmosphere. After 
purging, the flow of a reagent gas was started (30 ml/min), and 
heating was turned on. Upon achieving the desired tempera 
ture, the sample was held at this temperature under the 
reagent flow for a specified time. The furnace was switched 
off and the sample was allowed to cool to room temperature 
under the reagent gas flow. At the end of the experiment, the 
tube was purged with the inert gas for several hours to remove 
any traces of the reagent. Upon completion of the treatment, 
the quartz boat with the sample was removed from the tube 
and weighed again to determine weight change. 
Nanocomposites Preparation: 
PLLA (1 g) was dissolved in 10 ml of chloroform. A 
moderate amount of ND or ND-ODA calculated by weight 
US 9, 186,190 B2 
21 
percentage was weighed and put into 20-ml vial. After addi 
tion of 10 ml of chloroform, the mixture was placed under 
high power sonic for 30 min, then mixed with PLLA/chloro 
form solution immediately. The solvent in mixture was 
evaporated under stirring. The resulting thick film was used 
directly for further measurement. 
Mechanical Tests: 
Two kinds of ND powders were used: air-oxidized HC1 
purified ND, and hydrophobic ND terminated with long ali 
phatic chains of octadecylamine (ND-ODA). Both powders 
were supplied by NanoBlox, Inc. The hardness tests were 
performed on Wilson Rockwell Hardness Tester (Instron 
Worldwide Headquarters, Norwood, Mass., USA). Six-ten 
point for each samples were measured. 
In Vitro Biocompatibility: 
In view of the long-term goal of generating scaffolds for 
bone tissue engineering, the U2OS osteosarcoma cell line 
was used for the study of cell attachment and proliferation on 
PLLA/ODA scaffolds. 7F2 cells were routinely maintained in 
alpha minimum essential medium (CMEM) with 10% FBS, 
2.0 mM L-glutamine, 1.0 mM sodium pyruvate (VWR) in a 
5% CO, incubator at 37° C. The scaffolds were incubated 
with 5% fibrin for 30 minutes to enhance cellular attachment. 
Then, the scaffolds were transferred to 24-well plates and 
seeded with a density of 50,000 cells/well. After 3 days, the 
samples were fixed in 10% neutral buffered formalin for 1 
hour at room temperature and then left overnight in 1xpBS at 
4°C. The samples were washed once with 1xPBS, and the 
cells were permeabilized for 15 minutes in 0.2% Triton-X 100 
(Sigma-Aldrich, St. Louis, Mo.) in PBS (Cellgro, Manassas, 
Va.). Following a gentle wash in 1xRBS, the samples were 
incubated for 15 min in PBS containing 2 g/mL Hoechst 
33258 (bis-benzimide, Sigma-Aldrich) and 1 lug/mL 
rhodamine phalloidin (Phalloidin, TRITC-labeled, Sigma 
Aldrich). Samples were visualized on a Leica DMRX micro 
Scope equipped with the appropriate fluorescence filters. 
Digital images were acquired using a Leica 300F camera. 
Differential Scanning Calorimetry (DSC): 
The thermal properties of the pure PLLA, 3 wt % ND 
ODA/PLLA and wt % ND-ODA/PLLA composites were 
studied by DSC (TA Instruments DSC Q100, TA Instruments, 
New Castle, Del.), using 10 mg of various samples. All mea 
Surements were performed under nitrogen atmosphere at a 
heating rate of 10°C/min. All experiments were performed 
twice, yielding similar results. 
Nuclear Magnetic Resonance (NMR): 
The solid-state NMR experiments were carried out using a 
Bruker DMX500 (11.7T) spectrometeroperatingata Larmor 
frequency of 125.8 MHz for C. A tripletuned magic-angle 
spinning (MAS) probe was used. The 4 mm Zirconia rotor 
containing roughly 70 mg of sample was spun at 12.5 kHz 
with automatic spinning control. Recycle delays of up to 64s 
were used in direct polarization experiments while a recycle 
delay of 2 s was used in "H-C cross polarization experi 
ments. The 'Cand HTL/2 pulse lengths were 5 usandTPPM 
decoupling of H was used during detection. Tetramethylsi 
lane was used as an external chemical shift reference for C. 
Dynamic Light Scattering (DLS): 
ND-ODA particle size in PLLA/chloroform solution was 
measured at 20°C. in back scatter geometry using a Malvern 
Zetasizer Nano ZS (Malvern Instruments Ltd, UK) equipped 
with a 10 mW He Ne laser (633 nm). 
Transmission Electron Microscopy (TEM): 
For Transmission Electron Microscopy (TEM) of the ND 
ODA/PLLA films, the samples were sectioned at about 100 
nm with a diamond knife using an Ultramicrotome Leica 













transferred from water to 200-mesh CuTEMgrid. Samples of 
ND-ODA suspension in chloroform were dropped on the Cu 
TEMgrid with lacey carbon film and left to dry. TEM images 
were obtained with a JEOL, JEM 2100 microscope at 200 kV. 
Photographs at different magnification were taken from sev 
eral randomly selected spots on the grid to ensure that the 
results are representative. 
Scanning Electron Microscopy (SEM): 
To assess the morphology of 7F2 cells cultured on various 
ND-ODA/PLLA scaffolds by scanning electron microscopy 
(SEM), samples were dried with a critical point dryer (CPD, 
SPICPD 7501, West Chester, Pa.) and characterized with an 
XL-30 Environmental SEM-FEG (Philips) using an accelera 
tion Voltage of 10kV according to standard protocol (Lietal. 
2005, Biomat. 26:5999-6008). A total of 3-4 images from 
independent preparations were evaluated. 
Depth Sensing Indentation and Vickers Indentation: 
Depth sensing indentation was performed using an MTS 
NanoIndenter XP (MTS, Eden Prairie, Minn.) with a 17 um 
radius spherical tip. Indentation experiments were performed 
using continuous stiffness mode, according to the manufac 
turers instructions. All tests were recorded at a constant 
strain rate of 0.05s' up to an indentation depth of 1,500 nm 
and the maximum load was held for 10 s to record creep. 
Unloading was performed to 10% of the maximum peak load 
followed by an additional 30s hold segment for thermal drift 
correction. The modulus and hardness values were calculated 
after effective Zero point correction as recommended by 
Kalidindi et al. (Acta Mater 2008, 56:3523-32) from the 
initial 50 nm elastic indentation segment. Stress-strain data 
were derived using the nanoindenter stiffness signal which 
was analyzed as described in literature (Kalidindiet al., 2008, 
Acta Mater 56:3523-32). Each sample was tested 10 times 
and one representative (near the middle of the set) curve of 10 
was used for load-displacement and stress-strain analysis. 
Vickers indentation tests were performed with a LECO 
M-400 Vickers hardness testing machine using a testing force 
of 2.94 N. The indents were photographed with an Olympus 
PMG3 light microscope. 
X-Ray Diffraction (XRD): 
XRD patterns were recorded using a Rigaku SmartLab 
X-ray diffractometer (Rigaku Corporation, Japan) with Cu 
KC. Source. Samples were prepared by Solvent casting on 
silicon wafer. The data were collected with a step size of 0.01° 
(20) and count time 2s per step between 10 and 30° (Kruger 
et al., 2005, Carbon 43:1722-30). 
Real-Time Quantitative Polymerase Chain Reaction (RT 
qPCR): 
Total RNA was isolated with RNeasy Mini Kit (Qiagen, 
Valencia, Calif., USA). Genomic DNA was digested with 
RNase-free DNase set (Qiagen) according to the manufactur 
er's protocol. Following RNA isolation, the quality and quan 
tity of the extracted RNA were analyzed with a Nanodrop 
1000 (Thermo Fisher Scientific, Inc.). 0.6 g of RNA was 
reverse transcribed with high capacity cDNA reverse tran 
scription kit (Applied Biosystems, Foster City, Calif., USA). 
RT-qPCR was carried out using Taq-Man Universal PCR 
master mix (Applied Biosystems) and specific primers for 
osteocalcin (OCN, assay ID: Mm 03413826 mH) and alka 
line phosphatase (ALP assay ID: Mm 1187113 g1) on a 
Stratagene MX3000P QPCR system (Agilent Technologies, 
Inc., USA). A comparative Ct method was used for analyzing 
the targeted gene expression levels, which were normalized to 
the Ct value of Taqman R) murine housekeeping gene pepti 
dylprolyl isomerase A (cyclophilin A, PPIA, assay ID: Mm 
02342430 g1*). Relative fold of change was then calculated 
as 2^^. Each experiment was carried out independently 
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three times and each sample was analyzed in duplicate. Sta 
tistical significance of the data was evaluated as described 
below. 
Statistical Analysis: 
All biological experiments were performed at least three 
times. Wherever possible data are expressed as mean fstan 
dard deviation (SD). Statistical analyses were performed 
using either ANOVA one-way analysis or ANOVA two-way 
analysis when applicable and significance was considered at 
p<0.05. 
Example 1 
Preparation and Characterization of Derivatized ND 
Particles 
30 mg of ND, corresponding to compound 1 in reaction 
(IV) (UD90 grade, NanoBlox, Inc., USA), was purified by air 
oxidation and cleansed of metal impurities by boiling in 35% 
witHCl for 24 hours, and then refluxed with 50 mL of SOCl, (Sigma Aldrich) and 1 mL of anhydrous N,N-dimethylforma 
mide (DMF) (Sigma Aldrich), a well known catalyst for this 
reaction, at 70° C. for 24 h. 
(IV) 
O O 






After removing the brown-colored liquid, compound 2 in 
reaction (IV) was washed with anhydrous tetrahydrofuran 
twice, and then dried at ambient temperature in a desiccator 
under vacuum. About 30 mg of the acyl chloride derivative 2 
was stirred in a sealed flask with 1 g of octadecylamine, also 
known as ODA (Sigma Aldrich), at 90-100° C. for 96 hours. 
After cooling, excess ODA was removed by sonication with 
anhydrous methanol (Sigma Aldrich) 4-5 times. To remove 
adsorbed ODA, the material 3 in reaction (IV) was further 
purified by extraction with hot methanol in a Soxhlet appa 
ratus. To ensure complete extraction, it was repeated 10 times 
with fresh methanol. 
The sequence of reactions was monitored by FT-IR analy 
sis of the products 1-3 (FIG. 7). C=O stretch vibrations in an 
acyl chloride derivative of ND were shifted to a higher fre 
quency compared to the C=O band in ND, thus indicating 
the conversion of COOH into —COCl (spectrumb in FIG. 
7). Treatment of acyl chloride derivative with ODA resulted 
information of the amide III (spectrum din FIG. 7). IRAmide 
I and Amide II bands at 1650 and 1550 cm, respectively, in 
the spectrum of 3 (spectrum d in FIG. 7) provided a proof of 
covalent attachment of ODA through the amide bond forma 
tion, as opposed to physisorption of ODA. Other IR features 
of ND-ODA, such as strong C–H stretch vibrations at 2800 
3000 cm characteristic of long hydrocarbon chains, and the 
N-H stretch of the amino group at 3300 cm', could not be 
considered alone as proof of the amide 3 formation, because 














A UV Raman spectrum of ND-ODA 3 (FIG. 8) revealed 
typical features of nanodiamond: a broad and downshifted 
peak of diamond at 1327 cm and a broad intense peak at 
1630 cm. The unresolved peaks of C H (at -2980 cm) 
and N—H (at ~3200 cm) were also present in agreement 
with the structure 3. These latter Raman peaks overlapped 
with the second-order spectrum of sp carbon in ND. 
A model of a single ND-ODA particle is shown in FIG. 
18b. Analysis of ND-ODA by C NMR provided evidence 
for the covalent linking of the ODA chains to the surface of 
ND (FIG. 18c). In particular, signals of first, second, and 
perhaps additional carbon atoms of ODA in H to C cross 
polarization spectra of ND-ODA were missing due to inter 
actions of the atoms near the amine end of ODA with the large 
ND particle. Similarly, the missing signals of carbon atoms 
nearest to the amide bond have been reported before for ODA 
covalently linked to carbon nano-onions (Rettenbacher et al., 
2006, Chem, Eur. J. 12:376-87) and multi-walled carbon 
nanotubes (Xu et al., 2003, Chem. Phys. Lett. 375:598-604). 
The disappearance was due to a combination of broadening 
effects including the increased steric hindrance, variations in 
local structure, and the presence of paramagnetic species. 
These effects suggested a covalent linkage between the ND 
and ODA. As a result of this covalent linkage, ND-ODA is 
hydrophobic and strongly fluorescent in contrast to as-re 
ceived non-modified ND. FIG. 18d shows High Resolution 
Transmission Electron Microscopy (TEM) image of ND 
ODA particles with lattice fringes at 0.206 nm (111 planes 
of diamond) surrounded by, presumably, the ODA chains. 
Purified ND-ODA powder 3 was used in subsequent stud 
1CS 
Example 2 
Dispersion of Non-Functionalized and 
Surface-Functionalized NDs in PLLA 
Due to the long hydrocarbon chains linked to its surface, 
the ND-ODA could be easily dispersed in hydrophobic sol 
vents such as benzene, toluene, chloroform, and dichlo 
romethane. At the same time, it was immiscible with water 
and poorly miscible with hydrophilic organic solvents such as 
DMF, ethanol, methanol, and acetone. 
After being dispersed in toluene with ultrasonication, NDs 
completely precipitated within 1 hour (FIG. 9). On the other 
hand, ND-ODA without any sonication or other means 
formed a clear, stable pale yellowish (or brown at high con 
centrations) colloidal solution, which showed no visible pre 
cipitation over a week. Particle size measurements revealed 
100-300 nm ND-ODA agglomerates in toluene and chloro 
form (FIG. 9) in contrast to 5,000-9,000 nm agglomerates 
formed in DMF. No sonication, surfactants, or other special 
means of dispersing were necessary for ND-ODA. The solu 
bility of ND-ODA, based on gravimetric estimations, was ~4 
g/L in dichloromethane and ~3 g/L in toluene. 
To test the dispersion of ND in PLLA, mixtures of 6% wt 
ND and 6% wt ND-ODA in PLLA/chloroform were pre 
pared. The ODA/PLLA mixture was centrifuged at 500 rmp 
for 30 min and then kept still for 1 week without any stirring. 
During this time, there was no phase separation observed in 
the mixture (FIG. 10b). 
However, the suspension of ND/PLLA prepared in the 
same way in chloroform precipitated within 1 day of standing 
without any centrifugation (FIG. 10d). This result suggested 
that ND-ODA has better dispersion in chloroform/PLLA sys 
tem than ND. This result also suggests an interaction between 
ODA and PLLA. 
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The hydrodynamic diameter of ND-ODA in PLLA-chlo 
roform Solutions determined by Dynamic Light Scattering 
(DLS) was narrowly distributed around maxima at 33+3 nm 
for 1% wt NDODA/PLLA and 28-2 inn for 10% wt ND 
ODA/PLLA, respectively (FIG. 19a). Given the 5 nm diam 
eter of primary ND particles, one could conclude that the 
sizes measured by DLS correspond to aggregates of >5 par 
ticles. However, the length of an ODA chain linked to ND 
appears to be about a half of the diameter of an ND (2.5 nm, 
FIG. 18b), i.e. the diameter of ND-ODA primary particles 
could be as much as twice larger than 5 nm. Thus the hydro 
dynamic diameters measured by DLS are likely those of small 
ND-ODA aggregates composed of just a few particles. 
The dispersion of ND-ODA in a solid PLLA matrix was 
observed by TEM of ultrathin sectioned samples (100 nm 
thick) containing 1, 3, and 10% wt of ND-ODA. At 1% wt 
concentration, low resolution TEM images (FIG. 19b) sug 
gested Small ND-ODA agglomerates, tens of nanometers in 
size. No further increase in the agglomerates size or density 
was observed at higher concentrations (FIGS. 19.c and 19d), 
Instead, when the concentration was increased, intercon 
nected particle chains were formed (FIG. 19d). Thus, DLS 
measurements and TEM micrographs converge to a conclu 
sion that there is no strong agglomeration orphase separation 
of ND-ODA and PLLA in the composites up to, at least, 10% 
wt of ND-ODA. 
Example 3 
Mechanical Tests in PLLA 
Results were produced on PLLA with two kinds of ND 
powders: air-oxidized HCl-purified ND, and hydrophobic 
ND terminated with long aliphatic chains of octadecylamine 
(ODA) (Mochalin et al., “High temperature functionalization 
and Surface modification of nanodiamond powders. In 
“Materials Research Society Symposium Proceedings Bos 
ton, MA, USA, 2007, Vol. 1039, 1039-P11-03). The hard 
ness tests were performed on a Wilson Rockwell Hardness 
Tester (Instron Worldwide Headquarters, Norwood, Mass.). 
FIG. 11 depicts the hardness of the composites produced 
with ND and ND-ODA. The hardness increased about 2 times 
when adding 0.5% wt. of air oxidized HCl purified ND into 
PLLA. However, it decreased when adding more air oxidized 
HCl purified ND (1% wt) into the biopolymer. This behavior 
is similar to results of d'Almeida et al. (J. Reinf. Plast. Comp. 
2007, 26(3), 321-330) and is due to a poor dispersion of the 
purified but non-functionalized ND in the polymer. 
In contrast, addition of 1% wt of ND-ODA (functionalized 
ND) increased the hardness of the composite dramatically 
(>4 times). These results provide strong evidence of improve 
ment in mechanical properties produced with the use of func 
tionalized ND composites within biocompatible and biode 
gradable composites. 
Example 4 
Mechanical Tests in PA-11 (Polyamide-11) 
Compositions of PA-1 1/ND with up to 20% wt of ND were 
produced in the form of nanofibers and thin films from oxi 
dized and HCl purified ND (UD90-grade) supplied by Nano 
Blox. Addition of ND significantly improved mechanical 
properties of PA-11 films, raising their Young's modulus by a 
















Two kinds of ND powders were used: air oxidized HCl 
purified ND, and a special NH2-terminated nanodiamond, 
produced by selective conversion of the ND surface COOH 
groups into amino groups. NH2-terminated ND was expected 
to react with epoxy resin and form strong covalent ND/poly 
merinterface, resulting infurther improvement in mechanical 
properties of the composites. 
Compared to the neat epoxy samples (0% wt of ND), the 
samples with 5% wt of ND demonstrate higher Young's 
modulus and hardness (Table 1). Especially notable is the 
about two-fold decrease in creep rate (FIG. 12b) and the 
significant increase in hardness that were only observed for 
composites with aminated ND. These preliminary results pro 
vided an indication of improvement in mechanical properties 
of the composites with ND covalently bonded to the polymer 
chains. 
TABLE 1 
Young's modulus and hardness of epoxy with and without ND 
reinforcement. 
Sample Young's Modulus, GPa. Hardness, GPa. 
O% wt. ND 2.7 O.17 
5% wt. non-aminated ND 5 O.18 
5% wt. aminated ND 6.3 O.23 
Shown in FIG.20a are load-displacement curves for ND 
ODA/PLLA obtained by nanoindentation, Stress-strain 
curves derived from these data are illustrated in FIG. 20b. 
Young's modulus and hardness of the composites, calculated 
after effective Zero point correction (Kalidindi et al., 2008, 
Acta Mater. 56:3523-32), are presented in FIG. 20f. The 
experimental Young's modulus of the PLLA thin film was 
2.6+0.1 GPa, which agrees well with the value of 2.05 GPa 
reported for the amorphous PLLA film by Martin et al. (Poly 
mer 2001, 42:6209-19). The measured hardness of the PLLA 
film was 0.05+0.01 GPa. The modulus and hardness of our 
PLLA thin films were lower than those previously reported 
for PLLA samples produced by injection molding (Young's 
modulus 4.6 GPa and hardness 0.23 GPa.) (Wright-Charles 
worth et al., 2005, J. Biomed. Mater. Res A74A:388-96). This 
may be explained by different crystallinity of the present 
PLLA samples produced by Solution casting (more amor 
phous PLLA) and those reported in literature, which were 
Subjected to elevated temperature and mechanical drawing 
during the injection molding process (more crystalline 
PLLA). 
Introduction of ND-ODA into the PLLA matrix resulted in 
an increase in the mechanical properties at all concentrations 
studied (FIG.20?). Supplementation with 1% wt of ND-ODA 
yielded a 207% higher Young's modulus and 420% higher 
Meyer's hardness. Further increase in ND-ODA content pro 
duced a marked reduction of 35% in creep (FIG.20a) and led 
to a further, though less pronounced increases inhardness and 
modulus with smaller changes at higher ND-ODA loads. 
Similar effects were recently reported for ND/poly(vinyl 
alcohol) composites (Maitra et al., 2009, Solid State Com 
mun. 149:1693-97) where the most dramatic increase in 
Young's modulus and hardness occurred at very low concen 
trations of ND (0-0.2% wt). Thus the present experimental 
results suggest that even at low ND content a significant 
improvement in mechanical properties of the polymer matrix 
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may be achieved given the ND has good affinity and is uni 
formly distributed in the matrix. In the case of PLLA-based 
composites strongly hydrophobic filler, such as ND-ODA, 
are preferred, since this material has good affinity to PLLA 
and may be well dispersed in hydrophobic solvents (such as 
chloroform) that are used in solution casting of PLLA. The 
crucial role of the hydrophobicity of ND-ODA is emphasized 
by a comparison with the results for as-received hydrophilic 
ND terminated with oxygen containing functional groups 
(Osswald et al. 2006, J. Am. chem. Soc. 11635-42) (FIG.20?. 
last two rows). In contrast to ND-ODA, the additions of 1 and 
3% wt of the asr-eceived ND (UD90) did not produce any 
significant changes in Young's modulus and led to a much 
Smaller increase in hardness. Interestingly, when non-modi 
fied diamond particles with no affinity to the matrix were 
added, sometimes even a concentration-dependent decrease 
in mechanical properties of polymer matrix was observed, 
which may be due to poor dispersion and poor adhesion 
between the diamond particles and the matrix (d. Almeida et 
al., 2007, J. Reinforc. Plast. Compos. 26:321-30). 
Vickers indentation provided further evidence for a dra 
matic improvement in the elastic recovery of the ND-ODA/ 
PLLA samples. In contrast to a clear Vickers imprint in pure 
PLLA (FIG. 20c), an imprint left in a 10% wt ND-ODA/ 
PLLA was hardly visible (FIG. 20d), suggesting almost com 
plete elastic recovery in the latter case. To explain the 
observed improvement in mechanical properties of PLLA 
upon addition of ND-ODA, two possible mechanisms could 
be considered. First, the improvement could be due to intrin 
sic high hardness and Young's modulus of the nanodiamond. 
Second, the nanofiller could increase the crystallinity of the 
polymer matrix which also translates into higher hardness 
and Young’s modulus of the composite. To understand how 
ND-ODA influences the crystallinity of PLLA, X-Ray Dif 
fraction (XRD) patterns of pure PLLA and 10% witND-ODA/ 
PLLA thin films were recorded, both produced by solution 
casting. In order to compare the crystallinity, the XRD pat 
terns of the films were normalized to the maximum intensity 
without background correction (FIG. 20e). The diffraction 
from the crystalline regions that were present even in amor 
phous PLLA had several characteristic maxima, the two 
strongest are at 20 of ~17° and ~19 corresponding to a 
typical PLLA pseudoorthorhombic C. structure (Hoogsteen et 
al., 1990, Macromol. 23:634–42). These peaks were present 
in XRD pattern of the neat PLLA film (FIG.20e) on top of a 
well-pronounced amorphous halo from 100 to 200. The XRD 
pattern of 10% wt ND-ODA/PLLA film also showed clear 
Bragg peaks of PLLA crystalline phase at 20 of ~17° and 
~19 (corresponding to (110) crystal reflection; Wang et al., 
2001, Polymer 42:8965-73), with a significantly suppressed 
amorphous halo, which was indicative of increased crystal 
linity of the composite compared to the neat PLLA film. The 
peaks at ~17° were fit with Lorentz functions. FWHM (Full 
Width at Half Maximum) values obtained from the peak 
fitting are 0.563+0.007 for neat PLLA and 0.474+0.0070 for 
10% wt ND-ODA/PLLA. The narrower peak of 10% wt 
ND-ODA/PLLA provided further evidence of the higher 
crystallinity of ND-ODA/PLLA. Thus, well-dispersed ND 
ODA particles increased crystallinity of the PLLA matrix, 
which in turn led to the enhanced hardness and Young's 
modulus of the composite. 
Example 6 
Biocompatibility & Cellular Proliferation 
PLLA is amongst the most commonly used synthetic bio 













history. When PLLA is combined with nanodiamonds togen 
erate composites, the properties of the resulting material may 
differ from the original properties of PLLA. 
In order to assess the biocompatibility of ND-ODA/PLLA 
composites, osteosarcoma cells (U2OS cells) were seeded on 
pure PLLA and ND-ODA/PLLA (0.5% wt of ND-ODA) 
scaffolds, FIG. 13 shows the cell morphology after 3 days cell 
culture, demonstrating that ND-ODA/PLLA scaffold Sup 
ported cell attachment. The cell attachment on ND-ODA/ 
PLLA scaffold was as good as on pure PLLA scaffold, as 
visualized by nuclear staining with bisbenbenzimide (Ho 
echst 33258). This result indicated that the ND-ODA/PLLA 
composites are biocompatible and may be used for tissue 
engineering. 
ND is known to be less cytotoxic than carbon black or any 
other known carbon nanomaterial (Schrand et al., 2009, 
“From manufacturing to medical applications.” New York: 
Springer: 2099, p. 159-87). However, cytotoxicity may be 
affected by ND functionalization. In order to determine the 
toxicity and biocompatibility of ND-ODA, the effects of 
native and functionalized ND on murine 7F2 osteoblast cells, 
using the fluorescent alamarBlueTM (AB) assay, were tested. 
The exposure of the cells to either ND or ND-ODA in con 
centrations up to 100 ug/ml resulted in a slight (though sta 
tistically not significant) reduction in cell viability compared 
to control, i.e. untreated cells grown on tissue culturetreated 
polystyrene, TCP (FIG. 24). This result suggested that, in the 
presence of ND or ND-ODA, the cells survived and grew 
essentially normally. ND with diameters 2-100 nm at concen 
trations up to 1000 ug/ml are nontoxic for different cell types, 
Such as neuroblastoma, kidney, and epithelial cells (Schrand 
et al., 2007, J. Phys. Chem. B 111:2-7: Chao et al., 2007, 
Biophys. J. 93:2199-2208). The present results suggest that 
NDs with ODA attached are nontoxic for 7F2 osteoblasts. 
In addition to ND and ND-ODA powders, biocompatibility 
ofND-ODA/PLLA composites was also tested. In these stud 
ies, osteoblasts were seeded on scaffolds made of PLLA 
containing 0-10% wt of ND-ODA and, on glass and TCP 
substrates as controls. The osteoblasts proliferated similarly 
on all Substrates during the 6 days of culturing with only 
small, statistically insignificant differences (FIG. 25). FIG. 
21 illustrates a typical SEM image of the porous structure of 
the 10% witND-ODA/PLLA thin film produced through solu 
tion casting. Porous structure formed as a result of Solvent 
evaporation facilitated cell attachment and growth. Due to the 
presence of ND-ODA in the PLLA matrix, the film showed 
blue and red fluorescence under excitation at 360 and 555 nm. 
(seen as light areas in the figures: FIGS. 21b and 21c), which 
coincide with the porous structure observed under SEM. The 
clear fluorescence of the 10% witND-ODA/PLLA Scaffold in 
background of the 7F2 osteoblasts after 3 days post-seeding 
(FIG. 21d) indicated the possibility to monitor the composite 
degradation in situ. 
In order to assess the morphology and cytoskeletal archi 
tecture of 7F2 cells on ND-ODA/PLLA scaffolds, the cells 
were fixed after 48 h and 6 days post-seeding. Osteoblasts 
attached, spread, migrated, proliferated to confluence within 
6 days (FIG. 21d and FIGS. 22a-d) and formed nearly iden 
tical monolayers on PLLA and ND-ODA/PLLA, scaffolds. 
Scanning Electron Microscopy (SEM) images (FIGS. 22e-f) 
confirmed these findings: at day 6 post-seeding 7F2 cells have 
become fully confluent on both scaffolds. 
The effect of ND on 7 F2 osteoblast differentiation was 
quantified by RT-PCR for two osteogenic differentiation 
markers, i.e. ALP and OCN. The relative expression levels of 
these two genes in 7F2 cells cultured for 48 h and 1 week on 
three different scaffolds (PLLA, 10% wt ND-ODA/PLLA, 
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and 10% wt UD90/PLLA) were measured and compared to 
those in 7F2 cells cultured on TCP for 48 h (FIG. 23). Impor 
tantly, there was not any significant difference in the expres 
sion of osteogenic marker genes on any of the Substrates at 
both 48 and 1 week post-seeding. When comparing the data at 
one week to those at 48 h, a significant decrease in ALP gene 
expression was observed concomitant with a significant 
increase in OCN gene expression (p<0.05 by two-way 
ANOVA). In the present system, the results for both ALP and 
OCN gene expression levels are in line with the AB assay 
data, in that there was no significant difference in any of the 
“biomarkers' on any of the substrates. Taken together, the 
data from two independent biochemical/molecular assays as 
well as from immunocytoechemical staining Suggested that 
ND-ODA/PLLA composites with up to 10% witND-ODA are 
non-cytotoxic for 7F2 cells; they support 7F2 cell prolifera 
tion and osteogenic differentiation to the same extent as con 
ventional “gold-standards, such as TCP, and therefore may 
be used for tissue engineering and regenerative medicine. 
As illustrated above, ND-ODA/PLLA composites with up 
to 10% wt ND-ODA showed uniform ND-ODA dispersion 
and good affinity between the matrix and the filler. The 
mechanical properties of NDODA/PLLA composites were 
improved dramatically with the addition of ND-ODA: 1% wt 
of ND-ODA increased the hardness of the composites by the 
factor of 4; 10% wt of ND-ODA resulted in almost an order of 
magnitude higher hardness, 3 times higherYoung's modulus, 
and reduced creep. Cytotoxicity and biocompatibility experi 
ments in concert with osteogenic marker gene expression 
analysis demonstrated that both ND and ND-ODA are non 
toxic to murine osteoblasts, and Support cell proliferation and 
differentiation in vitro. The combination of these properties 
with intrinsic fluorescence and tunable biodegradability 
makes the ND-ODA/PLLA composites promising materials 
for bone tissue engineering and regenerative medicine. 
Example 7 
Thermal Analysis of ND-ODA/PLLA Composites 
In order to test the influence of ND on thermal behavior of 
PLLA, DSC scans were run for pure PLLA, 3% wt ND-ODA/ 
PLLA, and 5% wt ND-ODA/PLLA composites. The differ 
ential heat flow curves of PLLA and ND-ODA/PLLA com 
posites are shown in FIG. 14, indicating no thermal behavior 
change of the composites when adding ND-ODA into PLLA. 
The addition of ND-ODA resulted in a small shift in T. 
which could be considered as a machine error. Importantly, 
there was no phase segregation or secondary peaks visible in 
ND-ODA/PLLA composites, suggesting that the ND-ODA/ 
PLLA composites with the concentration of nanodiamond no 
more than 5% wt were homogeneous. 
Example 8 
GCS Results 
Polycaprolactone (PCL) and polyethylene oxide (PEO) 
were used as a model system for the development of continu 
ous, gradient porous structures. The blend was first mixed in 
a Brabender(R) batch mixer, resulting in a co-continuous struc 
ture, with a phase size in the micrometer range. To produce a 
structure with continuous pores, the blend was extruded with 
different dwell times in the extruder for thermal conditioning, 
and finally selectively dissolved in water and dried. It was 
found that thermal conditioning can be effectively used to 













PCL after dissolution of the PEO phase (FIG. 15). The blend 
was also injection molded into a cold mold. It was found that, 
for a 6 mm circular channel, a gradient structure was devel 
oped, with finer structure at the Surface and coarser structure 
in the center (FIG. 16). 
Example 9 
Degradation Test 
Degradation experiments were performed by incubating 
solid cylinders made of PCL 90/10 and 80/20 PCL-CaP 
(calcium phosphate) composites in both a physiological 
buffer (DMEM) and upon admixing blood proteins (DMEM 
with 10% FBS). The cylinders were harvested at different 
times, and the molecular weight distribution of partially 
hydrolyzed polymer was analyzed using high performance 
liquid chromatography (HPLC, Waters, USA) equipped with 
a refractive index detector. HPLC measurements were carried 
out at 25° C. and at a flow rate of 0.8 ml/min using THF 
(tetrahydrofuran) as an HPLC solvent. Polystyrene standards 
(Polyscience Co.) were used for calibration. 
The results indicated that the molecular weight of PCL 
decreased over time and that the effect was more pronounced 
in the presence of blood proteins (FIG. 17). During the time 
period of 6 weeks, the observed change was small (<1%) but 
measurable. The Small change was consistent with the fact 
that PCL has a longer ~2 years degradation time. 
INCORPORATION BY REFERENCE 
The disclosures of each and every patent, patent applica 
tion, and publication cited herein are hereby incorporated 
herein by reference in their entirety. 
While the invention has been disclosed with reference to 
specific embodiments, it is apparent that other embodiments 
and variations of this invention may be devised by others 
skilled in the art without departing from the true spirit and 
Scope of the invention. The appended claims are intended to 
be construed to include all such embodiments and equivalent 
variations. 
What is claimed: 
1. A nanocomposite material comprising poly-L-lactic 
acid (PLLA) and 1-10% by weight of octadecylamine-sur 
face-functionalized nanodiamonds (ND-ODA), wherein ND 




and wherein the Young's modulus of the nanocomposite 
material is between 5.1 and 8.0 GPa. 
2. The nanocomposite material of claim 1, wherein the 
ND-ODA are prepared by peptide bond formation between 
octadecylamine and a carboxylate group on the Surface-func 
tionalized nanodiamonds. 
3. The nanocomposite material of claim 1, further compris 
ing a composition comprising at least one bioactive agent 
selected from the group consisting of a bone healing drug, 
growth factor, bone cell, bone stem cell, antibiotic, and anti 
inflammatory drug. 
4. The nanocomposite material of claim 1, wherein the 
Meyer's hardness of the nanocomposite material is between 
0.20 and 0.51 GPa. 
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5. The nanocomposite material of claim 1, wherein there is 
no phase separation of ND-ODA and PLLA. 
6. A Surgical fixation screw, comprising: 
an interconnective porous shell, wherein said shell com 
prises a nanocomposite material comprising poly-L-lac- 5 
tic acid (PLLA) and 1-10% by weight of octadecy 
lamine-surface-functionalized nanodiamonds (ND 






and wherein the Young's modulus of the nanocomposite 
material is between 5.1 and 8.0 GPa, and 
a hollow core within said shell, wherein said hollow core is 
closed on the posterior end of said Screw and open on the 
anterior end of said screw. 2O 
7. The surgical fixation screw of claim 6, wherein said 
hollow core is optionally filled with a composition compris 
ing at least one bioactive agent selected from the group con 
sisting of a bone healing drug, growth factor, bone cell, bone 
stem cell, antibiotic, and anti-inflammatory drug. 25 
8. The surgical fixation screw of claim 6, wherein said 
posterior end is tapered with respect to said anterior end. 
9. The surgical fixation screw of claim 8, wherein said 
screw has full-length taper. 
10. The surgical fixation screw of claim 6, wherein said 30 
anterior end is without head. 
11. The surgical fixation screw of claim 6, wherein said 
posterior end is rounded and blunt. 
12. The surgical fixation screw of claim 6, wherein said 
shell has controllable varying coarseness, whereby phase of 35 
said nanocomposite material around said hollow core is 
coarser than phase of said nanocomposite material on outside 
Surface of said screw. 
13. The surgical fixation screw of claim 12, wherein said 
controllable varying coarseness is achieved through injection 40 
molding. 
14. A method of performing an orthopedic Surgery proce 
dure in a patient, comprising the steps of: 
32 
inserting a Surgical fixation screw in at least one orifice of 
a bone or tissue of said patient, wherein said screw 
comprises: 
an interconnective porous shell, wherein said shell com 
prises a nanocomposite material comprising poly-L- 
lactic acid (PLLA) and 1-10% by weight of octade 
cylamine-surface-functionalized nanodiamonds 




and wherein the Young's modulus of the nanocomposite 
material is between 5.1 and 8.0 GPa, and 
a hollow core within said shell, wherein said hollow core is 
closed on the posterior end of said screw and open on the 
anterior end of said screw, and 
filling said hollow core of said screw with a composition 
comprising at least one bioactive agent selected from the 
group consisting of a bone healing drug, growth factor, 
bone cell, bone stem cell, antibiotic, and anti-inflamma 
tory drug. 
15. The method of claim 14, wherein said posterior end is 
tapered with respect to said anterior end. 
16. The method of claim 15, wherein said screw has full 
length taper. 
17. The method of claim 14, wherein said anterior end is 
without head. 
18. The method of claim 14, wherein said posterior end is 
rounded and blunt. 
19. The method of claim 14, wherein said shell has con 
trollable varying coarseness, whereby phase of said nano 
composite material around said hollow core is coarser than 
phase of said nanocomposite material on outside Surface of 
said Screw. 
20. The method of claim 19, wherein said controllable 
varying coarseness is achieved through injection molding. 
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